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Abstract: 
Background: CT colonography (CTC) is a noninvasive technology used to screen for colorectal 
cancer. Unlike other screening modalities, CTC provides a view of the abdomen and pelvis 
allowing radiologists to detect lesions in extracolonic organs. There is much debate on the 
balance of potential benefits versus potential harms of discovering, working up and treating these 
extracolonic findings. This debate might be especially relevant for asymptomatic populations 
receiving screening with CTC. 
Purpose: This systematic review aims to determine the frequency and clinical implications of 
finding incidental, extracolonic lesions during CT colonography (CT) in asymptomatic, 
screening populations. In addition, this review reports the frequency and clinical outcomes of 
clinically important lesions. Lastly, this review summarizes the various methods studies used to 
define the clinical significance of incidental findings. 
Data Sources: I carried out a systematic search of MEDLINE, Embase, the Cochrane Clinical 
Trials databases and published reviews up to March 2012. 
Study Selection: Two investigators independently reviewed 282 abstracts and 53 full text articles 
using a set of predefined inclusion and exclusion criteria. Both reviewers carried out independent 
critical appraisals of each study using criteria developed by the United States Preventive Services 
Task Force. 
Data Extraction: One reviewer extracted information on study samples, designs, populations, 
interventions and outcomes from six studies. A second reviewer verified this information for 
accuracy. 
Data Synthesis: The frequency of extracolonic findings (ECFs) ranged from 27.2% to 68.9% 
(mean 49.3%). Included studies used similar classification systems of clinical importance, which 
were primarily based on the likelihood of clinical workup. Studies reported that 5.6% of the 
reported ECFs were of high clinical importance and 15.5% of lesions were either moderate- or 
high-importance. A minority of these findings represented lesions that could have benefitted 
from early diagnosis and intervention. Studies reported that 0.09% to 1.2% of subjects were 
diagnosed with AAAs and 0.23% to 0.88% were diagnosed with extracolonic cancers. Studies 
used widely varying lengths and methods of following ECFs, making it difficult to estimate the 
true clinical implications of incidental findings. However, the range of moderate/high to high-
importance findings (5.6% to 15.5%) provides a good estimate of the number of subjects 
requiring some clinical workup. 
Limitations: I identified several weaknesses of the available literature on ECFs from screening 
CTC. For instance, many included studies suffered from poor follow-up and incomplete 
reporting of outcomes. In addition, no studies properly addressed the potential physical and 
psychological harms of being diagnosed, worked up and treated for extracolonic findings. Lastly, 
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the included literature does not address how ECFs are handled in non-academic settings. This 
systematic review also had several weaknesses. The decision to limit the review to screening 
populations might reduce the strength of my findings. I attempted to compensate by including 
populations at high risk of CRC and studies conducted outside the US, but this might have 
reduced the generalizability of my findings. Furthermore, I were unable to adjust for different 
follow-up time periods, making it difficult to compare the clinical outcomes of ECFs among 
included studies. Lastly, I attempted to develop an outcomes table for ECFs from screening 
CTC, but were unable to do so because of the imprecision of results, variable periods of follow-
up and gaps in reported outcomes. 
Conclusions: Based on these results, a large proportion of individuals receiving CT 
colonography for colorectal cancer screening will have an extracolonic lesion discovered. 
Roughly one-fifth to one-third of these findings will receive some clinical workup and the 
majority of these will ultimately be diagnosed as benign. Since a small percentage of potentially 
important findings will result in clinical benefit, it is possible that the classification systems are 
overly sensitive. In addition, the reporting of all extracolonic findings might result in 
unnecessary testing and patient anxiety. Unfortunately, the existing data does not provide enough 
certainty to know which lesions can go unreported without putting the patient at harm. However, 
based on the evidence, it appears that most radiologists and primary care physicians err on the 
side of reporting findings, which also results in unnecessary harms to patients. Another source of 
unnecessary and potentially harmful care is the large variability in radiologist interpretation of 
extracolonic findings. Based on this review, there are no indications that the development of a 
standardized classification system of ECFs has successfully reduced this variation. There are two 
primary ways to improve this practice variability in the future. First, classification systems could 
be improved to provide more guidance, especially for findings that have an uncertain balance of 
benefits and harms. More primary research might be required before this is possible. Second, 
training programs for CTC should require specific training for interpreting ECFs, including the 
proper follow-up of specific findings. 
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Introduction 
 
Statement of Purpose: 
CT colonography (CTC) is a noninvasive technology used to screen for colorectal 
cancer.
1
 Unlike alternative screening modalities such as colonoscopy, CTC provides a view of 
the extracolonic abdomen and pelvis, which allows radiologists to detect lesions in several 
abdominal organs including the kidneys, liver and pancreas. For some, such incidental findings 
might be viewed as serendipitous discoveries that allow earlier intervention and improved 
outcomes. Alternatively, detecting such lesions could lead to harms such as unnecessary 
diagnostic workups, interventions and patient anxiety. In addition, the radiologic surveillance or 
intervention for extracolonic findings could carry significant financial costs that might affect the 
cost-effectiveness of CTC as a screening tool.
2
 
In this systematic review, I examined the frequency and clinical implications of 
incidental lesions detected during screening CT colonography (CTC). Characteristics of study 
populations and CTC techniques are reported to indicate which factors might influence the 
frequency of incidental findings. In addition to reporting the overall frequency of these findings, 
I provide estimates of the reported clinical importance of these findings. Many studies on 
incidental findings have categorized lesions as high, moderate and low clinical importance and 
the Working Group on Virtual Colonoscopy have proposed a similar classification system.
3
 
These categories are designed to inform clinical care with higher importance findings requiring 
surveillance or immediate intervention. In this review, I systematically assessed the methods 
study authors used to classify findings into categories of clinical importance. The methods used 
for categorizing incidental findings provides important context for assessing the reported 
frequency of findings deemed to be clinically important. This review assesses these classification 
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systems to determine how they might affect the frequency and workup of extracolonic findings 
and whether they are likely to reduce variability in clinical practice. 
This systematic review aims to inform radiologists and primary care physicians of the 
likelihood of finding incidental lesions during screening CTC, the clinical outcomes of detecting 
these lesions and the usefulness of classifying these findings by clinical importance. The last 
systematic review on the frequency and implications of incidental lesions was published in 2005 
and included 3 studies focusing on screening populations, although some of these studies 
included a large percentage of symptomatic patients.
4
 This previous review was thus unable to 
make a conclusion on the frequency and clinical implications of extracolonic findings in pure 
screening populations. My review, on the other hand, focuses specifically on asymptomatic 
populations that more closely resemble a general screening population for CTC. I thought it was 
particularly useful to focus on an asymptomatic population since it is possible that patients’ 
symptoms could be attributable to incidental lesions. In addition, there are many more ethical 
issues raised when diagnosing asymptomatic, healthy patients with findings detected 
incidentally. My review should also provide a unique view on classification systems for judging 
the clinical importance of extracolonic findings. Only one review, published in the Journal of 
Law, Medicine, and Ethics,
5
 has systematically assessed how study authors judge clinical 
significance of incidental findings. Therefore, this systematic review will provide an updated 
view of the frequency and clinical outcomes of incidental findings from CTC in a screening 
population and report how study authors classify the clinical importance of extracolonic lesions. 
I believe that such a review is important as lower radiation doses are used for CTC,
6
 as 
recommendation statements on interpreting and managing extracolonic findings are 
disseminated,
7
 and as more insurance plans cover CTC for colorectal cancer screening.
8
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Problems with Current Screening Technologies for Colorectal Cancer: 
Colorectal cancer (CRC) is the third most common cancer and the second leading cause 
of cancer deaths in the United States.
9
 CRC has a well-characterized preclinical period during 
which most tumors develop from precursor lesions. In addition, early detection and treatment of 
CRC reduces its mortality. All of these characteristics make it an appropriate candidate for 
screening. 
Screening for CRC has been a significant factor in its declining incidence and mortality 
in recent years.
10,11
 Consequently, the United States Preventive Services Task Force, the 
American College of Radiology and the US Multi-Society Task Force on Colorectal Cancer 
(USMSTF) all recommend colorectal cancer screening for individuals starting at age 50 or 
earlier for those with certain inherited syndromes or inflammatory bowel disease.
12,13
 Despite its 
demonstrated benefit and supporting recommendations, CRC screening is being underutilized by 
huge numbers of American adults aged 50 and older.
14
 There are many reasons for this, 
including the drawbacks associated with each individual screening technique. 
Colonoscopy is an increasingly preferred screening technology,
14
 potentially because of 
negative coverage decision by the Centers for Medicare and Medicaid Services
15
 and similar 
decisions by many other private insurers to cover colonoscopy.
16
 Colonoscopy also has high 
public perceptions of its accuracy
17
 and the demonstrated benefits of high sensitivity, high 
specificity and ability for immediate polyp removal.
13
 A long-term follow-up study of the 
National Polyp Study cohort reported a 53% reduction in mortality from colonoscopy and 
polypectomy.
18
 However, colonoscopy has several drawbacks that might reduce compliance 
including laborious bowel cleansing requirements, the need for sedation, patient discomfort 
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during the procedure and the risk of serious complications such as bowel perforation and serious 
bleeding.
19
 In a recent trial,
20
 patients who were recommended colonoscopy for CRC screening 
had a significantly lower rate of adherence compared to those offered FOBT or given a choice 
between FOBT and colonoscopy. In addition, colonoscopy might not be available for some due 
to its expense and the limited number of trained endoscopists.
21
 
Sigmoidoscopy might limit patient discomfort and the need for sedation, but it shares many 
of colonoscopy’s drawbacks. In addition, some have raised concerns that sigmoidoscopy misses 
important lesions in the proximal colon.
22,23
 One way to compensate for this lost sensitivity is 
pairing sigmoidoscopy with fecal occult blood tests (FOBT). Sigmoidoscopy every five years 
combined with yearly FOBT screening has been recommended as an alternative to 
colonoscopy.
12
 But FOBT has its own shortcomings, including its high risk of false positives, 
resulting in unnecessary additional endoscopies.
24
 
Double contrast enhanced barium enema (DCBE) is a CRC screening technique with good 
safety profile and a moderate cost
25
 but concerns about DCBE’s poor sensitivity to detect polyps 
have contributed to its decreased use in recent years.
26
 
 
Techniques of Screening CTC: 
 After first being described in 1994,
27
 CT colonography or virtual colonoscopy has 
emerged as a new, non-invasive technique for CRC screening.
28
 CTC involves a helical, thin-
section CT of a distended and cleansed colon, providing data that can be reconstructed into two- 
and three-dimensional images.
29
 Bowel cleansing for CTC consists of patients maintaining a 
clear liquid diet for 24 hours and cathartic cleansing with laxatives, similar to conventional 
colonoscopy. Tagging liquid and fecal material is possible with the oral administration of barium 
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and/or iodine contrast.
29
 For CTC it is necessary to distend the bowel by blowing room air or 
carbon dioxide through a catheter into the rectum.
30
 Bowel distension helps avoid missing 
lesions hidden by undistended or collapsed segments of bowel. After preparation, CT scanning is 
performed with the patient in supine and prone positions to help differentiate between polyps and 
stool. 
There are several CT characteristics that must be considered by radiologists carrying out 
CTC, including slice thickness, radiation dose and the use of IV contrast. Recommendations on 
slice thickness state that it should not exceed 3 mm when using multi-detector computed 
tomography (MDCT) on screening populations.
31
 There are several ways to change the radiation 
dose in CTC including increasing pitch and slice collimation, decreasing the voltage (kVp) or 
current (mAs) or employing automatic exposure control in smaller patients.
32
 The appropriate 
radiation dose has been a moving target, as researchers attempt to reduce the potential for 
iatrogenic injury. Investigators have taken advantage of the high contrast between the colonic 
mucosa and air in order to reduce radiation doses.
6,33
 A recent study by Macari et al. reported 
excellent detection of polyps larger than 10 mm with significantly lower radiation doses.
34
 Ultra-
low dose protocols, which set the current to the lowest setting possible (10 effective mAs or 40 
electric mAs) and cut the dose used by Macari et al. by 80%, have also proven effective for 
detecting polyps.
35
 While these studies show that ultra-low doses of radiation can be used to 
detect polyps, such doses might not be sufficient for detecting extracolonic lesions. Using low 
tube currents decreases the number of photons that reach detectors and thus increases image 
noise, which is less of an issue for detecting polyps due to the high contrast between the 
intracolonic air and the colonic mucosa. In addition, low radiation doses might provide adequate 
penetration for obese patients.
29
 Another consideration is the use of IV iodine contrast, which 
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might improve the diagnostic quality of CTC. But due to its extra cost, requirement for IV access 
and the risk of anaphylactic allergic reactions, IV contrast is not currently recommended for 
screening CTC.
31
 
 
Acceptance of CTC in the United States: 
CTC for colorectal cancer screening had delayed early acceptance, likely resulting from 
conflicting reports on its sensitivity for detecting polyps.
8
 Some concerns were addressed by the 
National CTC Trial,
36
 a trial with 2,531 individuals in 15 centers, reported 90% sensitivity and 
86% specificity for detecting large adenomas. Nevertheless, this study involved only specially 
trained radiologists and did not report detection of lesions < 5 mm. In addition, reported 
sensitivities and specificities of CTC for screening have been more heterogeneous and less 
encouraging in low-risk populations.
29
 
These weaknesses, in addition to concerns of the implications of extracolonic findings, 
contributed to the USPSTF’s negative recommendation for CTC as a cancer screening technique 
in 2008.
19
 The same conclusion was reached by the American College of Physicians in their 
updated recommendations in 2012.
37
 In contrast, in 2008 CTC was endorsed as an appropriate 
CRC screening technique by the American Cancer Society, American College of Radiology 
(ACR) and the U.S. Multisociety Task Force on Colorectal Cancer.
38
 
There are indications that CTC has not won over primary care physicians, who play a 
large role in recommending screening tests for colorectal cancer. Only a minority (23%) of 
surveyed primary care physicians in the U.S. felt that CT colonography was very effective at 
reducing colorectal cancer mortality. Less than 5 percent of these surveyed physicians said they 
routinely recommend CT colonography for CRC screening. 
39
 It is unclear whether these views 
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would be dramatically affected by a positive recommendation for CTC by the USPSTF or a 
change in Medicare reimbursement for CTC. 
 
Indications and Advantages of Screening CTC: 
There are several reported indications for screening CTC. For instance, CTC is a useful 
option after a failed optical colonoscopy.
40,41
 Failed colonoscopy occurs in roughly 5% of 
patients as a result of patient discomfort, colon tortuosity, adhesions from previous surgeries or 
hernias.
28
 CTC can also be used to evaluate the colon proximal to an obstructing colon cancer, 
although bowel preparation can be challenging if obstruction is near-complete.
42,43
 CTC might 
also be used for patients with contraindications to endoscopy. Common contraindications for 
colonoscopy include advanced patient age, severe comorbidities, predisposition to severe 
bleeding or prior adverse reaction to sedation.
28
 Due to its need for colonic distension, CTC also 
has several contraindications including acute abdominal pain, recent abdominal surgery, 
entrapment of colonic loops from abdominal wall hernia or acute inflammatory conditions (acute 
diverticulitis, active Crohn’s disease or ulcerative colitis and toxic megacolon).44-46 CTC can also 
be used for patients who refuse other CRC screening options. Lastly, it’s possible that CTC 
could be considered a primary option for colorectal cancer screening in the near future.
47
 
There are several advantages of CTC that might make it more acceptable to some patients 
and providers. First, CTC shows sensitivity and specificity for adenomas >10 mm comparable to 
colonoscopy, which is currently the gold standard.
19
 This might make CTC more acceptable to 
those who worry about the variable sensitivity and specificity of FOBT and sigmoidoscopy. 
There is the promise of advances in technology that could lead to improved computer-aided 
polyp detection techniques in the near future.
48,49
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CTC might also be more acceptable to patients concerned about the discomfort of 
colonoscopy, although there are some inconsistencies in studies looking at this issue. Some 
studies have shown that patients receiving CTC report less pain than during colonoscopy,
26,50,51
 
although other studies report just the opposite.
52-54
 These differences are likely explained by 
whether investigators used spasmodic bowel agents or sedation.
55
 If fecal and fluid tagging 
procedures improve, the pendulum of patient acceptance might swing in favor of CTC, 
especially since bowel preparation is viewed as one of the most onerous features of CTC.
56
 
Another advantage to CTC is the decreased risk of serious complications such as bowel 
perforation, serious bleeding and adverse effects of sedation.
28
 Since sedation is not required for 
CTC, patients are not required to secure a ride from the procedure and, compared to 
colonoscopy, can return to work sooner. 
 
Concerns with CTC: 
 In addition to the need for full bowel preparation and the need for colonic insufflation, 
there are several concerns with using CT colonography for CRC screening. First, it is very 
difficult, if not impossible, to detect flat or small (< 5 mm) colonic lesions with CTC.
57
 CTC also 
involves radiation exposure and the associated risks of iatrogenic malignancy,
58
 although these 
risks will probably be reduced with low-dose protocols for screening CTC.
29
 Furthermore, past 
cost-effectiveness analyses of CTC report that it is the most expensive modality for detecting an 
adenoma.
59
 
Incidental findings are one feature of CTC that has been described as both an advantage
60
 
and a flaw
61
 of this technology. Early detection of lesions such as abdominal aortic aneurysms or 
extracolonic malignancies might allow for early intervention and improved prognosis. But 
- 11 - 
 
detection of some AAAs or cancers might lead to unnecessary patient anxiety from being labeled 
with a serious condition, overdiagnosis and overtreatment. It is difficult to weigh these potential 
benefits and harms of detecting such life-threatening lesions. CTC might also detect benign 
lesions that could be misidentified as being clinically important. It is possible that a patient could 
be subjected to significant inconvenience, radiation exposure and possibly surgery for what turns 
out to be a benign finding. In the face of these uncertainties, it is difficult for radiologists and 
primary care physicians to know how to properly address incidental findings detected during 
screening CTC. 
 
Important Factors in the Frequency of Incidental Findings: 
There are several factors that might influence the frequency of extracolonic findings 
including CT technique, patient features and radiologists’ detection thresholds. These factors are 
important when comparing the relative frequencies of incidental findings reported in the 
literature. In addition, these factors might affect the generalizability of findings for different 
screening populations in the United States. 
Radiation dose is one aspect of the CT technique that might influence the ability to detect 
incidental lesions. In light of reductions in radiation for CTC, the frequency of extracolonic 
findings might decrease with emphasis on reduction of radiation doses for screening CTC. Low-
radiation protocols might also limit the specificity of initial diagnoses of incidental lesions, 
potentially making it difficult to determine the clinical significance of an extracolonic finding. 
Another important CT factor is the use of IV contrast. Since IV contrast is also not recommended 
for screening CTC, its ability to correctly diagnosis incidental findings may be reduced. One 
study comparing the incidence of extracolonic findings in symptomatic patients receiving CTC 
- 12 - 
 
reported that lesions were found in 71% of those who received IV contrast compared to 29% of 
those who underwent an unenhanced scan.
62
 Lastly, CT slice thickness might influence the 
detection of extracolonic findings, with thinner slices leading to increased detection of lesions. 
There are several patient factors that might affect the detection of incidental findings. It is 
important to take patient age into consideration, especially since CRC screening is generally 
recommended for patients age 50 or older. In addition, the presence of symptoms might 
influence the detection of incidental findings or the likelihood of these lesions being reported. 
Therefore, reported frequencies from cohorts of symptomatic patients might be less applicable to 
screening populations. Lastly, the a-priori risk of colorectal cancer could affect the frequency of 
extracolonic findings. The accuracy of various screening techniques for detecting polyps might 
also vary for low- and high-risk patients. Lastly, the ACR White Paper on CTC states that 
screening CTC is contraindicated for certain high-risk patients (e.g. hereditary polyposis or 
nonpolyposis cancer syndromes).
32
 
The radiologist’s level of training might impact the likelihood of following up on an 
incidental finding. In a retrospective analysis of radiologist reports in the U.S., the odds of 
recommending additional imaging decreased by 15% with each decade of radiologist 
experience.
63
 In addition, experience in community settings have shown that CTC experience 
does not substitute for proper training.
64
 In light of these findings, frequencies of extracolonic 
findings from studies performed at academic medical centers might be less applicable to 
community hospitals or outpatient endoscopy suites. There might also be a temporal trend 
towards increased detection of incidental findings. After adjusting for potential confounders, 
radiologists in 2008 were 2.16 times as likely to recommend additional imaging than radiologists 
in 1995.
63
 Lastly, the use of multiple radiologists to corroborate results might influence the 
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detection of incidental findings. Supporting this, large, prospective studies have reported large 
interobserver variability among radiologists interpreting CTC.
65-67
 
 
Pressures to Address Incidental Findings: 
The American College of Radiology’s Incidental Findings Committee wrote that many 
physicians are unwilling to accept diagnostic uncertainty in the face of incomplete data, a lack of 
clear diagnostic and treatment algorithms, fear of litigation and a desire to adhere to the “better 
safe than sorry” philosophy.7 To help address these concerns, the ACR developed a set of rules 
with the aim of “optimizing” utilization of imaging when addressing incidental lesions.7 They 
have released specific diagnostic and treatment guidelines for incidental findings in the kidneys, 
liver, adrenal glands and pancreas. The recommendations include separate considerations for 
low-dose, unenhanced CT examinations, like CTC. While the recommendations attempt to 
provide straightforward guidance to radiologists in order to reduce unnecessary further workup, 
there are several weaknesses with their coverage of low-dose unenhanced CT. First, there were 
many gaps in the evidence, making it difficult for them to develop truly evidence-based 
recommendations. For instance, they found no studies addressing the management of lesions 
found during unenhanced CT including lesions in the kidneys, liver, adrenal glands and pancreas. 
Furthermore, the White Paper did not address how to handle lesions of the lungs, stomach, small 
bowel, ovaries, gallbladder, retroperitoneum, uterus, prostate, urinary bladder and bone. In 
addition, the ACR recommendations concede that formulaic recommendations are not always 
appropriate since patient factors, such as age or comorbidities, might change a physician’s 
approach to workup and treatment. This is especially true for screening CTC, since screening 
populations are generally older and thus may have a different frequency of incidental findings or 
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require a more conservative surveillance and treatment strategies.
39
 In light of these concerns, the 
recommendations provided by the ACR might be less helpful for guiding clinicians who discover 
incidental findings during CRC screening with CT colonography. 
The Working Group on Virtual Colonoscopy has published a classification system of 
incidental findings (Table 1) as part of the CT Colonography Reporting and Data System (C-
RADS).
3
 This effort was designed to provide a standardized method for characterizing the 
clinical importance of incidental lesions on CTC in order to minimize excessive costs and 
unnecessary patient anxiety. Incidental lesions are classified as E0-E4, in a way similar to the BI-
RADS classification system for screening mammography.
68
 As indicated in Table 1, E2 findings 
should not receive workup, by definition. E3 findings are incompletely characterized lesions with 
work-up that is subject to local physician practice and patient preference. E4 findings are 
potentially important findings that should be communicated to the referring physician (e.g. 
primary care provider or gastroenterologist). These are likely to require further workup or 
immediate treatment. 
While the C-RADS system provides a helpful framework, it is unclear how often these 
definitions are used in clinical practice or research protocols. Since this standardized system has 
only been introduced fairly recently, it is likely that many of the studies reporting incidental 
findings from CTC have used different definitions for the clinical importance of findings. 
 
Table 1. C-RADS Classification of Extracolonic Findings on CTC 
(Adapted from Zalis et al.
3
) 
 
 Description Examples 
E0 
Limited Exam 
Compromised by artifact; evaluation of 
extracolonic soft tissues is severely limited 
N/A 
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E1 
Normal Exam or Anatomic Variant 
No extracolonic abnormalities visible. 
Retroaortic left renal vein 
E2 
Clinically Unimportant Finding 
No workup indicated 
a. Liver, Kidney: simple cysts 
b. Gallbladder: cholelithiasis without cholecystitis 
c. Vertebra: hemangioma 
d. Hiatal hernia 
E3 
Likely Unimportant Finding, Incompletely 
Characterized 
a. Kidney: minimally complex or homogenously 
hyperattenuating cyst 
b. Small lung nodule 
E4 Potentially Important Finding 
a. Kidney: solid renal mass 
b. Ovarian mass 
c. Lymphadenopathy 
d. Vasculature: aortic aneurysm  
e. Lung: non-uniformly calcified parenchymal 
nodule ≥ 1 cm 
 
It is unclear how these classification systems were developed and how they might impact 
clinical practice. For instance, non-uniformly calcified, large (≥ 1 cm) lung nodules are 
considered potentially important, but it is unclear how to classify small, calcified nodules or 
large, uniformly calcified nodules. In addition, it is unclear which classifications require workup 
or intervention. Two of the most serious clinical findings, extracolonic malignancies and 
abdominal aortic aneurysms (AAAs), have significant clinical heterogeneity that might require a 
more nuanced workup and treatment. Lastly, the reliability or validity of this classification 
system has not been independently assessed. As a result, this classification system has not been 
endorsed or widely applied in practice. A survey of 1600 radiologists asking about the approach 
to incidental findings at chest CT demonstrated a wide variability in practices and a substantial 
deviation from recommended medical practice.
69
 It is therefore possible that even the best 
classification systems for addressing incidental findings has a limited effectiveness on clinical 
practice. Furthermore, there are indications that non-radiologist physicians have a poor grasp of 
recommendations for CTC.
70
 This is important since primary care physicians, not radiologists, 
are responsible for the workup that ensues from detecting extracolonic lesions on CTC. 
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Summary: 
To address the low uptake of colorectal cancer screening, CT colonography might be 
used increasingly to screen average risk adults. In fact, President Obama underwent a CTC for 
colorectal cancer screening during his most recent presidential physical.
71
 Third-party payers 
might soon reimburse colorectal cancer screening of average-risk adults with CTC, leading to its 
widespread adoption. Such a development would increase the number of incidental, extracolonic 
lesions detected during screening CTC. Currently, radiologists and primary care physicians face 
conflicting information regarding the proper approach to extracolonic findings. In the face of this 
uncertainty, this systematic review reports the frequency of extracolonic findings in CTC used 
for screening for colorectal cancer, including how many of these findings were considered to be 
clinically important. This review also reports how study authors classified the clinical 
importance of lesions and the potential effects these determinations have on the workup and 
treatment of incidental findings. It would be informative for both radiologists and primary care 
providers to know the extent of testing required to achieve diagnostic certainty. Standardized 
classification systems and algorithms will not necessarily improve care, even if they standardize 
care, since they have not been validated. In addition, large inter-rater variability might limit the 
usefulness of classification systems and reduce the generalizability of reported frequencies of 
clinically important incidental findings. 
 
Key Questions: 
 This review aims to address the following questions: 
(1) What is the overall frequency of incidental lesions detected during screening CT 
colonography? 
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(2) What is the frequency and clinical outcomes of incidental lesions deemed to be of 
high, moderate and low clinical importance? 
(3) How do the authors of studies determine how to classify the clinical importance of 
incidental lesions? 
 
Methods 
In addition to reporting the frequency and clinical implications of extracolonic findings 
on CTC, I aimed to determine whether each study’s distribution of high, moderate and low 
importance findings and the rationale provided for these classifications. In addition, I explored 
the potential benefits and harms of detecting extracolonic findings. While it is impossible to 
determine definitively whether detecting incidental findings will result in a net benefit,
72
 in this 
review I have attempted to use information on the natural history of individual lesions to develop 
probabilistic estimates of potential harms and benefits to patients. A search of systematic reviews 
was conducted and revealed that no recent reviews have focused specifically on the frequency 
and clinical implications of incidental findings specifically for screening CT colonography. 
 
Eligibility criteria: 
I limited the review to randomized controlled trials, cohort studies and high-quality case 
series. I reviewed systematic reviews and meta-analyses for references and commented on any 
their unique conclusions, but their findings were not included in my results to avoid duplicate 
counting of studies. Studies were required to identify the incidence of extracolonic lesions 
detected from screening CTC. 
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I based my inclusion/exclusion criteria for study populations to find patients that would 
best represent a screening population. As such, I excluded studies with 15% or more 
symptomatic patients. I also limited my review to studies with at least 75% patients between the 
age of 50 and 74 years old. When not enough information was provided to determine whether the 
study met these age criteria, I estimated the percentage of subjects aged 50 to 74 years old 
assuming uniform distribution. This age range was chosen to match the USPSTF 
recommendations for colorectal cancer screening.
73
 I also chose to include only studies looking 
at CT colonography without IV contrast, in accordance with guidelines for screening CTC.
32
 I 
considered applying a cut-off value for CTC radiation doses, but opted against doing so since 
radiation doses for CTC continue to change as technologies improve. I excluded studies 
including patients with a personal history of colorectal cancer. However, I included studies with 
subjects at higher risk for colorectal cancer, including those with a personal history of polyps, 
polyposis syndrome or family history of cancer. The studies that included high-risk subjects were 
considered separately from studies with low-risk screening populations. I considering limiting 
this review to studies looking at U.S. practices, given the heterogeneity of patient populations 
and the variability in radiologist experience and training.
74
 However, the implications of 
incidental findings affect CTC programs beyond the U.S. In addition, many of these sources of 
variability, including radiologist training, experience and type of institution, are present within 
the United States. I therefore included studies from all settings and countries. To account for the 
potential variability introduced by including non-U.S. studies, I collected information on the 
setting of the study intervention and training of the radiologists. I did not consider any 
comparators for CT colonography since extracolonic findings are not detected during any other 
screening tests for colorectal cancer. In addition, I excluded studies that did not follow up 
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incidental findings and only reported frequency of extracolonic lesions from initial CTC. 
Furthermore, I only considered RCTs and cohort studies for inclusion in the final review. The 
full PICOTTS inclusion and exclusion criteria are listed below in Table 2. 
I excluded studies with inadequate reporting of methods, population, interventions or 
outcomes. The full reporting criteria used to judge studies are included in Appendix B.  
Two reviewers independently reviewed the titles and abstracts of studies identified during 
the searches and included studies based on the criteria listed above. When the reviewers 
disagreed or the abstract did not contain enough information to apply the criteria, the full article 
was reviewed. Disagreements were settled by consulting with a third investigator. 
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Table 2. PICOTTS framework for review of incidental findings in CTC  
 
Category Inclusion Criteria Exclusion Criteria 
Population 
 
Predominantly asymptomatic patients age 50-
74 being screened for colorectal cancer with 
CT colonography 
 
 
- Studies with less than 75% of patients age 50-
74 years old 
- Studies including greater or equal to 15% of 
symptomatic patients 
- Studies including patients with personal 
history of colorectal cancer 
Intervention 
 
Standard technique screening CT colonography 
(i.e. low-dose, non-contrast enhanced CTC) 
 
 
- Diagnostic CTC (e.g. IV contrast) 
- MRI colonography 
- PET/CT 
Comparators 
 
N/A 
 
N/A 
Outcomes 
 
- Primary outcomes: 
o Frequency of extracolonic lesions 
Frequency of high, moderate and low 
clinical significance extracolonic 
findings 
o Frequency of N0M0 extracolonic 
cancers and AAAs 
o Number of follow-up procedures (e.g. 
imaging, invasive procedures, surgeries) 
o Unnecessary procedures (i.e. for benign 
findings) 
o Patient anxiety 
 
- Secondary outcomes: 
o Reported methods of determining 
clinical importance of clinical findings 
(high, moderate, low) 
 
Failure to report the frequency of extracolonic 
findings 
Timing of 
Effect 
 
Incidental findings and their resulting clinical 
implications reported at any time post-
screening CTC 
 
Studies that report no follow-up of patients with 
extracolonic findings. 
Timing of 
Search 
 
All studies published before March 4, 2012 
 
Setting 
 
Any setting for screening CTC including 
hospitals, outpatient radiology suites and 
primary care clinics 
 
Study 
Designs 
 
- Randomized controlled trials and cohort studies 
- Systematic reviews and meta-analyses can be 
used if PICOTTS are deemed to be equivalent 
to this review 
 
Case-control studies, case reports, high-quality 
case series 
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Search strategy: 
 To identify original research on this topic, I conducted a systematic search of MEDLINE, 
Embase and the Cochrane Clinical Trials databases. I searched PubMed on March 4, 2012 using 
the following search: “(colonography[tw] OR virtual colonoscopy[tw] OR colography[tw] OR 
CT colonoscopy[tw] OR virtual endoscopy[tw]) AND (extracolonic[tw] OR incidental*[tw] OR 
incidentaloma*[tw] OR serendipitous[tw]).” The search was adapted for Embase, which was 
accessed via Elsevier. A research librarian was consulted for the development of the search 
terms, which can be found below in Appendix A. I also performed manual searches of systematic 
reviews, included studies and background articles to find additional studies missed by my search 
strategy.  
I placed no date or language limits on the search to avoid missing studies that had not yet 
been indexed. I performed an updated search, using the same search parameters, three months 
following the initial search to identify any studies published since the initial search. I imported 
citations into an Endnote (Thompson Reuters, New York, NY) electronic database. 
 
Data extraction: 
One reviewer extracted data on study samples, designs, populations, interventions and 
outcomes using a standardized spreadsheet. These data were verified by a second reviewer and 
discrepancies were resolved by consensus. 
I extracted information on study methodologies such as the method of sampling (e.g. 
whether subjects were selectively studied or were consecutive cases), whether data collection 
was prospective or retrospective and the funding sources or potential conflicts of interest. I 
determined whether studies excluded previously diagnosed extracolonic findings. In addition, I 
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extracted the study’s methods for determining classifications of clinical importance. I recorded 
the number of observers (radiologists), the training level of radiologists, whether the study was 
set in a community or academic setting and where the study was based. Lastly, I recorded the 
clinical specialty of study authors and any potential conflicts of interest. 
I also collected information on study populations including age, ethnicity, presence of 
symptoms, risk of colorectal cancer. I obtained information on interventions including CT factors 
such as slice thickness, radiation dose, use of supine and/or prone exam and whether IV contrast 
was used. I extracted information on outcomes including the frequency of extracolonic findings 
from selected studies and the number of lesions with high, moderate and low clinical importance. 
Since these definitions varied among authors, I collected information on findings that might be 
considered life-extending: the number of “early” (N0M0) cancers and AAAs.4 For AAAs, I used 
the definition from the USPSTF, which defines AAAs as expansions of the aorta below the renal 
arteries to a diameter greater or equal to 3 cm.
75
 This is likely a conservative definition for 
potential clinical importance since the only two conditions with evidence supporting survival 
benefit from screening with abdominal imaging are AAA
76
 and renal cell carcinoma.
77
 In 
addition, many of these diagnoses will represent aneurysms and cancers that would have never 
have otherwise become clinically apparent (i.e. are “overdiagnosed”). Lastly, I gathered 
information on the number of recommendations for additional imaging (RAIs), surgeries, 
biochemical investigations, medical treatments and clinical appointments. 
 
Assessing the Internal Validity of Studies: 
 I assessed the quality, or internal validity, of studies by applying the rules used by the 
United States Preventive Services Task Force (USPSTF).
78  I rated the internal validity/risk of 
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bias of studies as good, fair or poor quality. These ratings were based on my assessment of the 
recruitment of patients (i.e. consecutive sampling), maintenance of groups (i.e. attrition, cross-
overs, adherence, contamination), the measurement of outcomes (i.e. equal, valid and reliable), 
consideration of all important outcomes, description of study populations, description of 
intervention, consideration of potential confounders and sample size. In addition, I developed 
quality criteria specific to my topic. The full quality criteria are included in Appendix C.  Poor 
quality studies were defined as those with a fatal methodological flaw, such as more than 40% 
patient dropout. Fair quality studies had a few methodological flaws but no fatal flaws. Good 
quality studies had one to no methodological flaws. I hypothesized that the methodological 
quality of studies contributed to the likely heterogeneity of reported outcomes. I explored this 
hypothesis after grading each study’s internal validity. I also assessed the power of studies as 
part of my quality assessment. I excluded studies with inadequate power (n < 50), since these 
results would be more susceptible to random variation. 
Two reviewers independently made judgments on internal validity and analysis/power of 
studies. Disagreements were settled through consultation with a third investigator. 
 
Assessing the Generalizability of Studies: 
 To assess the external validity of studies, I used the guidance provided in the USPSTF 
procedure manual with some minor adjustments.
78
 I used information gathered for each study’s 
populations, settings and interventions to assess how closely each resembled an asymptomatic 
population receiving colorectal cancer screening with CTC. I also used the GRADE Working 
Group’s definition of directness to help guide this assessment of generalizability.79 I judged each 
study’s directness based on characteristics of the study population such as age, presence of 
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symptoms and risk of colorectal cancer. I also considered each study’s setting, training and 
number of radiologists and CT colonography technique. Two reviewers independently graded the 
external validity of studies as good, fair or poor (full descriptions in Appendix D). 
Disagreements were settled through consultation with a third investigator. 
 
Data Synthesis and Analysis: 
For outcomes data, I collected the reported frequencies of extracolonic findings from 
CTC reported in each study, including the classification of findings into high, moderate and low 
clinical importance. I reported the number of recommendations for additional imaging, surgeries, 
medical treatments, confirmed diagnoses and unknown diagnoses for findings. Lastly, I 
attempted to estimate the potential harms of the workup, treatment and surgeries. 
I also analyzed patient and CT factors to judge whether there were any clear variables 
that might affect the frequency of extracolonic findings or the likelihood of recommending 
additional imaging or treatment. When reported, the prevalence of extracolonic findings in those 
determined to have colorectal cancer was considered separately, since these patients require an 
abdominal CT scan for staging purposes. 
Given the subjectivity of interpreting CT colonography scans for extracolonic findings, I 
decided that the heterogeneity of findings would preclude a quantitative data synthesis. The 
heterogeneity of included studies was not formally assessed but I did collect information on the 
various methodologies and their risks of bias to provide some indication on the potential sources 
of variability. For completeness, I used PRISMA reporting guidelines for systematic reviews.
80,81
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 I did not carry out a formal assessment of potential publication bias. I did, however, 
assess published studies for selective reporting of results by assessing the outcomes reported in 
the methods section compared to the results section. 
 
Strength of Evidence: 
 To assess the strength of evidence, I applied the approach used by the USPSTF.
78
 When 
applicable, I assessed each of the six critical appraisal questions used by the USPSTF (see 
Appendix E). Since this review considered no comparators, I considered well-done, large, 
prospective cohort studies to be of near-equal value to randomized controlled trials. By 
evaluating the internal and external validity grades of individual studies, I assessed the aggregate 
internal and external validity of the body of evidence for each key question. I judged the 
consistency of evidence by looking at the variability in outcomes between studies and whether 
there were clear differences in study methodologies or populations that accounted for the 
differences. Lastly, I assessed directness by asking how well study populations, interventions and 
outcome measures fit my key questions. In other words, I evaluated how generalizable each 
study was to a typical screening population receiving CT colonography for colorectal cancer 
screening. Based on these elements, I graded the quality of evidence as high, moderate, low or 
very low. The full description of these ratings can be found in Appendix F. 
 
Results 
 Searches, performed between March 4, 2012 and March 8, 2012, identified 282 titles and 
abstracts, including 44 past reviews, commentaries or letters. An additional 15 studies were 
identified by hand-searching these previously published reviews, editorials and commentaries. 
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After both reviewers performed a title and abstract review, 53 titles remained for full text review. 
During the full text review, 43 studies were excluded for invalid publication type/study design (n 
= 11), wrong intervention (n = 5), invalid study population (n = 14), incorrect outcomes (n = 6), 
poor quality (n = 4) and inadequate reporting (n = 3). After an extensive review of reporting and 
quality criteria, an additional 3 studies were excluded for inadequate follow-up of patients 
following CTC. Disagreements between reviewers on inclusion/exclusion of 6 studies were 
settled by consensus. Two studies
82,83
 performed at the University of Wisconsin had overlapping 
dates of enrollment. Study authors concluded that these studies had overlapping datasets, so I 
decided to exclude the study published in 2010
83
 since the reporting of outcomes was more 
complete for my population of interest in the 2008 study.
82
 After removing this duplicate study, 6 
cohort studies (2 prospective and 4 retrospective) met my final inclusion criteria and were 
included in the systematic review. An updated search performed on May 28, 2012 identified 4 
new studies, which were all excluded for incorrect PICOTTS. A flow diagram of my search 
results and exclusion of studies is displayed in Figure 1 below.  
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Figure 1. Flow diagram of search strategy 
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Included Studies: 
The six studies included a total of 6,316 subjects with a mean age of 59.9 years old 
(range 26-90). All of these six studies were cohort studies (4 retrospective, 2 prospective), five 
were conducted in the United States and one was based in Australia. The studies included 
subjects with varying levels of risk for colorectal cancer. Table 3 contains summaries of these 
studies’ characteristics. 
 
Internal Validity 
 I assessed the quality of included studies using the USPSTF criteria for internal validity 
including measurement bias, confounding bias and selection bias. 
Included studies had varying potentials for measurement bias resulting from the CTC 
technique and method of reading scans. Equality of measurement was judged based on the use of 
a single CTC technique and standardized system of clinical importance. Half of studies included 
CTC scans performed on different scanners with varying radiation dose and slice thickness, 
increasing the risk of measurement bias. In addition, only half of studies used a standardized 
system for judging the clinical importance of ECFs. 
I judged the validity of measurements based on the use of a classification system based 
on the system of judging clinical importance, the exclusion of previously-diagnosed ECFs and 
the method of following ECFs. Almost no studies used valid measurement criteria for reading 
and interpreting CTC scans. Only one study
60
 assessed each lesion’s likelihood of benefiting 
from diagnosis or treatment. Furthermore, several studies failed to exclude previously diagnosed 
ECFs, which are likely to be treated differently than newly diagnosed findings. Furthermore, 
only a few studies had a method of follow-up that was likely to capture all resulting workup. 
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Most studies relied on their institution’s electronic medical record without accounting for 
investigations, treatments or procedures delivered at other institutions. 
The reliability of measurements was also highly variable. Most studies employed 
adequately trained radiologists. However, only three studies
60,84,85
 used duplicate reading of CTC 
scans. Only one of these studies
86
 specified that the two radiologists performed their 
interpretations of scans independently. Moreover, only two studies
33,85
 explicitly stated that 
radiologists were blinded to past radiological scans and patient history.  
Potential confounding bias was noted in two studies
82,84
 which reported higher average 
age, more comorbidities and a higher likelihood of intracolonic findings among those with ECFs. 
These same studies noted that older, sicker populations were less likely to receive clinical 
workup for their ECFs. While the risk of confounding bias is likely to be small, there was not 
enough information provided to determine its magnitude in most studies. Three out of the six 
studies
33,85,86
 failed to report any information on potential confounders and the remaining studies 
reported only a few relevant variables. Patient enrollment was unlikely to contribute bias, as 
most studies consecutively enrolled individuals referred to their institutions for screening CTC. 
No studies provided information on the subjects who were lost to follow-up (i.e. did not receive 
all or part of their clinical workup at the same institution), making it difficult to assess the 
potential for selection bias introduced by differential loss to follow-up. However, all studies were 
able to follow at least 70% of their population. 
The full quality assessment and final grades of internal validity can be found in Appendix 
G below. 
 
Populations 
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 Almost all studies included a group of consecutive patients who took part in their 
institution’s CTC screening program. The only study that did not enroll consecutive patients84 
invited a randomly-selected group of patients from the community to participate. One study
60
 
required that patients be referred from a gastroenterology clinic in the local area and, similarly, 
another recruited patients referred to their institution for CRC screening, guaiac-positive stool or 
incomplete colonoscopy. 
 
Settings and Description of Radiologists 
These studies were predominantly conducted in the United States, with the exception of 
one study conducted in Australia.
84
 All studies were conducted at academic medical centers, 
including one
60
 conducted at a military medical center. 
The degree of CTC-specific training varied greatly between studies. Two studies
60,86
 
enrolled participating radiologists in a training program in which they read 50 pathology-proven 
CTC cases, in accordance with the American College of Radiology’s recommendations for CTC 
training.
87
 Other studies
82,84
 reported that participating radiologists had reached this 
recommended threshold through their clinical experience. The remaining two studies
33,85
 stated 
that their radiologists were experienced and board-certified. However, these studies did not 
report the radiologists’ CTC-specific training. 
Half of the six included studies
60,84,85
 had multiple radiologists review the CTCs and this 
review was conducted independently in only one of these three studies.
85
 This review was 
performed retrospectively on the initial reads of CTC scans. Those subjects with “clinically 
important” (C-RADS E3 or E4) extracolonic findings discovered retrospectively were reassessed 
to confirm the finding and determine why it was missed initially. Two studies
33,85
 required that 
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radiologists were blinded to patient’s previous imaging and medical history. In addition, none of 
the included studies reported whether CTC readers were blinded to the purpose of their project. 
In fact, several studies
82,84,86
 employed study authors to read and interpret CTCs for the study. 
 
CTC Parameters 
 All studies used multidetector CT scanners (4-, 8-, 16-, 64- and/or 124-detector rows) and 
some used single-slice detector CT scanners as well.
33,85
  Each study scanned patients in both the 
supine and prone positions and none used IV contrast material. Studies showed wide variations 
in slice thickness, reconstruction interval and pitch. Radiation levels also varied, with currents 
ranging from 40-100 mA. Each study used a CT scanner with a peak voltage of 120 kV. Only 
one study
84
 calculated the total radiation dose, reporting that each scan resulted in less than 5 
mSv (total effective body dose)
2
. 
 Three of the studies
60,82,84
 used a standardized CTC technique for all subjects. Two of the 
studies without a standardized technique
85,86
 were retrospective and had a range of CTC 
parameters corresponding to the ones used by different radiologists in their institution. In the 
remaining study,
33
 subjects underwent multi- or single-detector scans. The currents of the 
multidetector scans were adjusted to match the image noise of the single-slice technology. 
 
Definitions of Clinical Importance of ECFs 
 Most of the included studies
60,85,86
 applied the C-RADS classifications published by the 
Working Group on Virtual Colonoscopy.
3
 These were applied retrospectively in these studies, 
with the exception of one
60
 which began applying it prospectively while their study was ongoing. 
Two of these studies classified lesions further – one classified them based on their need for 
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additional workup
85
 and the other labeled lesions that were particularly high-risk.
60
 Two of the 
studies that did not use C-RADS were conducted before the Working Group on Virtual 
Colonoscopy published this classification system. These studies
33,84
 classified extracolonic 
lesions based on their need for further workup, similar to the C-RADS system. In the final 
study,
82
 radiologists prospectively labeled findings as moderate or greater importance or minimal 
or no potential importance depending on the need for further workup or clinical importance of 
the findings themselves, if diagnostic. The full descriptions of clinical importance classification 
systems used are found in Table 4 below. 
 Despite the homogeneity in classification systems, similar clinical findings were often 
classified differently in different studies. For instance, lung nodules were described as both 
moderate- and high-importance. Most studies did not further characterize lung nodules by size or 
appearance (i.e. calcification or speculation). In addition, one study
60
 characterized cystic masses 
of the ovary as high importance but classified complex ovarian cysts as moderate importance. 
Similarly, cystic pancreatic lesions were classified as high-importance
33
 while pancreatic cysts 
were labeled as moderate importance
60
. Osteoblastic and osteolytic bone lesions were classified 
as both moderate and high clinical importance. Conflicting classification was also applied to 
mesenteric lymph nodes and splenic artery aneurysms. As was the case with pulmonary nodules, 
lesions of the kidneys, liver, adrenal glands and ovaries were inadequately characterized by study 
authors. Lastly, studies rarely provided an explicit definition for AAAs. One study
84
 reported at 
least 1 AAA with a diameter < 3 cm, others
85
 only reported aneurysms ≥ 3 cm and another 
study
60
 separately reported “high-risk” AAAs as those with a diameter ≥ 5 cm. 
 
Method of Following ECFs 
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The studies had widely varying study lengths ranging from a mean follow-up time of 1 to 
2 years. Only one study
84
 set a defined follow-up duration (2 years) from the time of CTC. Other 
studies based their follow-up duration and clinical endpoints. For instance, one study
86
 searched 
subjects’ medical records solely to confirm completion of the imaging studies recommended 
during the initial CTC read. Another study
33
 focused only on post-CTC imaging studies and did 
not report on subsequent clinical appointments, biochemical investigations, medical treatments, 
surgeries or other invasive procedures. On the other hand, four studies
33,60,82,84
 reported on the 
surgeries performed subsequent to CTC. Some of the retrospective studies tried to collect 
information on all medical workup performed subsequent to the subject’s CTC, but their 
methods for collecting this information were not always clear. Most studies failed to explicitly 
report a duration or specific endpoint that would end their follow-up of ECFs. 
Some studies reported the follow-up investigations received by all study subjects. Others 
limited the scope to subjects with high clinical importance findings (i.e. C-RADS E3 and E4) 
lesions since, by definition, lesions below this threshold were not supposed to receive workup. 
One study
84
 determined that subjects follow up with a radiologist, general practitioner or 
appropriate specialist depending on the clinical importance of their finding (e.g. specialist for 
high clinical importance lesions) and the recommended workup (e.g. radiologist for imaging). In 
another study,
85
 information on ECFs was passed on to subjects’ primary care physicians at the 
time of the initial CTC and all subsequent medical workup initiated by the PCP was collected 
from subjects’ medical records. 
The included studies used several different sources of information to determine what 
follow-up investigations occurred. For instance, most
33,60,82,85,86
 employed a review of subjects’ 
electronic medical records to gather information about workup of ECFs. Only one of these 
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studies
60
 reported the percentage of subjects whose subsequent workup would be captured by 
this system. For the others, it was unclear how often subjects received follow-up that would not 
be captured by their electronic medical record. Conversely, one study
84
 had all subjects receive 
their follow-up exams at a single institution thus ensuring that they could account for all 
subsequent imaging, procedures and treatments. 
 
Frequency of Incidental Findings 
 The method of tallying extracolonic findings varied among studies. For instance, some 
studies included previously detected extracolonic findings while others excluded them or 
reported them separately. One study
84
 included only extracolonic findings that had changed 
significantly since the last time they were imaged. In addition, other studies only reported 
extracolonic findings they deemed to be of high or moderate clinical significance. The full 
description of methods of tallying ECFs and number of ECFs detected is included in Table 5 
below. 
 Four of the six studies
33,60,84,86
 reported the frequency of subjects with extracolonic 
findings. Among these studies, the frequency of subjects with at least one ECF during their 
initial CTC ranged from 27.2% to 68.9% (mean 49.3%). Two of these studies
33,84
 reported the 
total number of ECFs, ranging from 1.2 to 1.8 ECFs per subject with an extracolonic lesion 
detected. Three of the other studies
60,83,86
 did not report the overall frequency of ECFs at all. The 
other
85
 only reported the number of ECFs for the entire population, which included symptomatic 
and high-risk subjects. This study reported that among all subjects, 272 of 376 (72.5%) had at 
least one extracolonic finding. Among these 272 subjects, investigators found 520 incidental 
lesions (average 1.9 ECFs/subject). 
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 Two studies reported the number of extracolonic findings found that were missed on the 
initial CTC. One study
85
 reviewed all initial CTC scans and reports, stating that 144 E2, 29 E3 
and 4 E4 lesions were missed by the initial reader. Based on these numbers, they calculated an 
8.8% miss rate for E3 and E4 findings. Another study
33
 reported the ECFs not reported on the 
initial CTC that were discovered during the subsequent radiological workup. They noted 44 
lesions (23 of medium- or high-importance) that were not reported on the initial CTC report. 
Their retrospective read of the initial scan was able to see 25% of these findings on the initial 
CTC. The remaining 75% could only be seen on scans taken as part of the radiological workup. 
 
Frequency of Clinically Important Lesions 
 The method of determining clinical significance varied somewhat among studies. Study 
authors sometimes based clinical importance on the lesion’s characteristics and some based it 
retrospectively on the final diagnosis. For studies using the C-RADSs classification system 
(Table 1), I considered E4 findings to be high significance and E3 findings to be moderate 
significance. By definition, E2 lesions do not require clinical workup
3
 and therefore were not 
included in either of these groups. The methods of reporting ECFs and reported frequencies can 
be found in Table 5 below. 
In the four studies reporting high-importance lesions separately,
33,60,84,85
 their frequency 
ranged from 1.5% to 10.4% (mean 5.6%). In one of these studies (frequency of high-importance 
findings = 7.4%),
84
 there was no separate category for moderate importance extracolonic 
findings. Other than this study, all others reported the combined frequency of moderate- and 
high-importance ECFs. The frequency of moderate- and high-importance findings ranged from 
4.4% to 37.3% (mean 15.5%).  
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To address the heterogeneity between classification systems, I also looked at the number 
of abdominal aortic aneurysms, diagnosed early (N0M0) cancers, total cancers and lesions 
suspicious for cancer. In the three studies
33,60,84
 that reported the number of abdominal aortic 
aneurysms diagnosed during the initial CTC the frequency of AAAs ranged from 0.088% to 
1.2%. The study
84
 reporting a frequency of 1.2% (5 of 432 subjects) stated that they found 6 
AAAs with diameters of 2.8 to 4.5 cm. Since I defined AAAs as ≥ 3 cm and this study did not 
report the individual diameters of each aneurysm, only 5 of these AAAs were counted although 
there might have been fewer that were ≥ 3 cm. In the study including symptomatic patients, there 
was no separate reporting of outcomes for their average-risk population. However, they reported 
a newly diagnosed AAA in 1 subject (0.19%). The remaining two studies either stated total 
number of aneurysms in the aortoiliac system
82
 or did not report individual outcomes.
86
 
Four studies
33,60,82,84
 reported the number of newly discovered cancers, which were 
diagnosed in 0.23% to 0.88% of subjects (mean 0.45%). The frequency of N0M0 cancers was 
discussed in two studies,
60,84
 which reported early stage cancers among 0.13% and 0.23% of 
subjects. The frequency of lesions suspicious for malignancy had wide variation and was often 
unclear due to poor characterization of lesions. The complete list of diagnosed AAAs, 
malignancies and suspicious lesions are included in Table 7 below. 
Chin et al.
84
 reported that 5 subjects (1.2%) had AAAs, 1 subject (0.23%) had a newly 
discovered cancer and no additional subjects had lesions suspicious for malignancy. This newly 
discovered cancer was a noninvasive renal cell carcinoma. Veerappan et al.
60
 reported AAAs in 2 
subjects (0.088%) and early-stage cancers in 3 subjects (0.13%), including one stage 1a lung 
adenocarcinoma and two stage 1 renal cell carcinomas. In addition, this study reported subjects 
with stage IIIb nodular lymphoma, recurrent bronchoalveolar carcinoma and stage II renal cell 
- 37 - 
 
carcinoma, totaling 6 subjects (0.26%) receiving cancer diagnoses. Gluecker et al.
33
 reported 4 
subjects (0.59%) with AAAs and 6 subjects (0.88%) with cancer diagnoses, including 1 
squamous cell carcinoma of the lung, 1 renal adenocarcinoma, 1 renal oncocytoma and 3 ovarian 
serous cystadenomas. In addition, they reported 77 lesions suspicious for malignancy, 
representing 8.9% of all ECFs. This study did not report the number of N0M0 cancers. 
 
Clinical Implications of Incidental Findings 
 The duration, methodology and reporting of follow-up varied greatly among studies. The 
number of subjects requiring some workup ranged from 2.0% to 8.7% (mean 5.4%). After 
excluding studies that did not report surgeries or invasive procedures,
85,86
 the mean increases to 
7.4%. One study
33
 did not state how many subjects required workup but did report the number of 
individual tests and procedures required. 
Most studies reported primarily the imaging workup required. CTs and ultrasound scans 
encompassed the bulk of recommended or performed imaging tests, making up 52.8% and 35.0% 
of all imaging tests, respectively. The complete list of imaging studies can be found in Table 8 
below. In addition to the imaging reported in Table 8, Veerappan et al.
60
 noted that subjects 
received 6 bone scans, 3 upper endoscopies and 1 bronchoscopy. There were also some scans 
reported in Pickhardt et al.
82
 that are not listed in Table 8, including 1 skeletal scintigraphy scan, 
2 renal scintigraphy scans and 3 small-bowel capsule endoscopies. 
The four studies that listed surgeries reported that, of the 370 subjects requiring workup, 
48 surgical procedures were performed. The majority of reported surgeries were for AAA repair 
or treatment of suspected malignancy. The full summary of these findings can be found in Table 
6 below. 
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There were also several procedures for lesions that were ultimately found to be benign. 
One study
84
 specifically reported this number, stating that 75% (24 of 32) of findings receiving 
workup were ultimately diagnosed as benign. Another study
82
 reported that while adnexal lesions 
accounted for 45% (10 out of 22) of all surgeries, all lesions proved to be benign and all 10 liver 
lesions receiving contrast-enhanced CT were eventually diagnosed as benign. The same study 
stated that pulmonary nodules discovered on CTC led to chest CT in 6 subjects, CT-guided lung 
biopsy in 4 subjects and thorascopic resection in 2 subjects. One of these pulmonary nodules was 
found to be malignant. In a separate study,
60
 none of the 8 patients receiving surgery for a pelvic 
mass ultimately had a malignancy and one of the 2 AAA repairs were on aneurysms they 
considered to be “low risk.” However, the majority of studies did not explicitly report the 
number of potentially unnecessary procedures performed for benign findings. 
There were many other clinical outcomes that were omitted from the majority of these 
studies. For instance, only two studies
33,84
 reported the number of medical treatments required. 
One of these studies
84
 reported that no subjects required medical treatment. The other study
33
 
reported that one subject required chemotherapy for thyroid cancer metastases to the lungs and 
another received antihelmintic treatment for ileal ascaris.  
An especially glaring omission was discussion of harms from this additional workup, 
especially considering the description of its potential benefits. For instance, only one study
82
 
discussed the complications resulting directly from workup, stating that there were no reported 
complications of surgeries or invasive procedures. In addition, no studies calculated subjects’ 
exposure to ionizing radiation during the subsequent radiological workup or discussed the 
potential harms of surgeries for benign findings. These surgeries carry the possibility of 
complications but also the inconvenience and cost of a surgical procedure and the resulting 
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recovery. Lastly, the studies failed to collect data on the potential psychological harms from 
extracolonic findings, such as the anxiety of a potentially serious diagnosis. 
 
Funding Sources and Potential Conflicts of Interest 
 None of the six studies reported their funding sources and only one included study
86
 
reported conflicts of interest. This particular study reported that authors had no potential conflicts 
of interest. However, the study that was excluded for duplicate data
83
 reported relevant conflicts 
of interest for some of the authors from the study I included.
82
 These authors were consultants 
for companies that develop computer software for CTC and the cofounders for a company that 
provides educational materials and trainings on CT colonography. 
 
Generalizability of Studies: 
 I assessed the external validity of each study using criteria developed from the USPSTF
78
 
and the GRADE working group.
79
 I judged the generalizability of study populations, settings and 
interventions to a typical screening population. 
I defined a typical population as one that was primary asymptomatic, at average-risk of 
colorectal cancer and within the recommended screening ages of 50-74. Three studies
60,82,84
 were 
rated as having good population external validity. The one study with a fair rating
86
 primarily 
enrolled screening patients but also included those with an incomplete colonoscopy. I gave the 
remaining two studies
33,85
 poor generalizability ratings due to their inclusion of symptomatic and 
high-risk patients without any separate reporting of outcomes. 
I defined a typical setting as some mixture of academic and non-academic institutions. 
All included studies were conducted in academic settings with no inclusion of community 
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hospitals. Therefore, these results of these studies are likely more generalizable to academic 
settings alone. 
I defined a typical intervention as a non-contrast-enhanced, low-dose CTC interpreted by 
radiologists with varied levels of experience, but with the recommended 50 endoscopically-
confirmed cases (if skilled at abdominal CT) or 75 cases (if unskilled at abdominal CTC).
32
 None 
of the included studies used IV-contrast for their CTCs. The voltage of 120 kVp was consistent 
with those reported in a recent survey of screening CTC programs.
88
 The effective tube current 
levels, however, were slightly higher than the surveyed programs, which all reported currents 
less than 50 mAs. In addition, almost all included studies in my review used highly trained 
radiologists to read and interpret CTCs. While this might increase the internal validity of their 
results, it might also make them less generalizable to most CRC screening programs, especially 
those in community settings. Furthermore, a few studies
60,86
 retrospectively applied clinical 
importance classifications without blinding radiologists to subsequent medical or radiological 
history. This practice is not representative of the technique of reviewing and interpreting CTCs 
in clinical practice and thus might reduce the generalizability of these findings. As a result, the 
two studies that interpreted CTCs retrospectively, without masking, were given poor/fair 
generalizability scores for intervention. 
Overall, I judged all the studies to have fair external validity, meaning that these studies 
differed a few ways from the standard CT colonography screening program. I conclude that it is 
moderately probable (50%-89%) that the experience with CTC described in this study would be 
attained in a typical screening population. All the generalizability grades can be found in 
Appendix H below. 
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Overall Results and Strength of Evidence 
 The first key question addressed by this review was the overall frequency of incidental 
lesions detected during screening CTC colonography. Based on the reported studies, there is 
evidence of low strength that at least 30% of subjects will have at least one extracolonic finding 
found on CT colonography. In addition, there is evidence of moderate strength that this 
proportion is higher among asymptomatic patients at high-risk of colorectal cancer. 
 The second key question assessed the frequency and clinical implications of moderate- 
and high-clinical importance extracolonic findings. There is evidence of low strength that 10% or 
lower of individuals receiving screening CTC will have high clinical importance findings. There 
is also evidence of low strength that the frequency of moderate or high frequency findings ranges 
from 10% to 30%. The majority of high importance findings and the vast majority of moderate/ 
high importance findings will eventually be diagnosed as benign. Moderate strength evidence 
supports the fact that roughly 2% of subjects receiving CTC will have an incidentally discovered 
AAA or extracolonic cancer.  There is also moderate strength evidence that almost all findings of 
high importance will receive some clinical workup. The evidence strength for workup required 
for moderate/high importance findings or all ECFs is very low.  
 Lastly, I set out to find out how studies were determining the clinical significance of 
extracolonic findings. Since the development of the C-RADS criteria in 2005,
3
 most studies have 
used this classification system. However, despite using a uniform system, studies show 
variability in the classification of some lesions. 
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Table 3. Description of studies 
Author 
(Year) 
Study Design Country 
Number of 
Subjects (N) 
Age of Subjects 
(range &/or S.D.) 
Risk of 
CRC 
Percent 
Symptomatic 
Description of CTC Readers 
Chin et al. 
(2005)
84
 
Prospective 
cohort 
Australia 
432 
(230 M, 202 F) 
Mean 59 yrs. 
(range 50-69) 
Average risk 0% 
 
2 readers (concurrent review) 
 
At least 100 CTCs reviewed previously 
 
Academic center 
 
Pickhardt et 
al. (2008)
82
  
Retrospective 
cohort 
US 
2195 
(996 M, 1199 F) 
Mean 58 yrs. 
(S.D. 8.1) 
NR
a
 0% 
 
1 reader 
 
Range of 1-5 years interpreting CTC studies 
 
Academic center 
 
Flicker et al. 
(2008)
85
 
Retrospective 
cohort 
US 
527 (210 avg. risk) 
(genders not 
reported
b
) 
Mean 61 yrs. 
(range 26-89) 
Both average 
and high-risk
c
 
0%
d
 
 
2 readers (reinterpretation of original read 
specifically for this study) 
 
Abdominal imaging fellow and experienced 
abdominal imaging attending 
 
Academic center 
 
 
NR: Not reported 
a
 Stated that the subjects were “representative of typical U.S. screening population” but did not have exclusion criteria for high-risk 
b
 For the 272 subjects with E2-E4 findings there were 101 males and 171 females 
c
 Separate analysis for average risk patients 
d
 Patients within low risk group were not symptomatic 
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Table 3 (continued). Description of studies 
Author 
(Year) 
Study Design Country 
Number of 
Subjects (N) 
Age of Subjects 
(range &/or S.D.) 
Risk of 
CRC 
Percent 
Symptomatic 
Description of CTC Readers 
Gluecker et 
al. (2003)
33
 
Prospective 
cohort 
US 
681 
(426 M, 255 F) 
Median 64 yrs. 
(range 26-89) 
High risk
a
 0% 
 
1 reader 
 
Each with 10 years of practice 
 
Academic center 
 
Macari et al. 
(2011)
86
 
b
 
Retrospective 
cohort 
US 
204 
(110 M, 94 F) 
Mean 53 yrs. 
(range 41-64) 
Mixed risk
c
 
10.9% 
(all with 
guaiac+ stool) 
 
1 reader 
 
Readers had 8, 14, 30 and 32 years of experience 
and either completed CTC course or had read > 
100 CTCs 
 
Academic center 
 
Veerappan 
et al. 
(2010)
60
 
Retrospective 
cohort 
US 
2277 
(1207 M,1070 F) 
Mean 61 yrs. 
(S.D. 11) 
NR
e
 NR
f
 
 
2 readers (each scan with significant findings 
reinterpreted by radiologist) 
 
All had routinely read CTCs, reviewer had read 
more than 5000 CTCs 
 
Academic center  
 
 
NR: Not reported 
a
 First-degree relative with colorectal cancer or polyps, prior personal history of polyps or colorectal cancer, or new onset of asymptomatic anemia 
b
 Only included younger cohort since this group fit into the inclusion criteria for age distribution 
c
 Included subjects with guaiac-positive stool 
d
 Subjects referred for screening but no exclusion criteria for high risk 
e
 Likely to be primarily average-risk subjects since authors state that high-risk patients are generally excluded from this screening program 
f
 Assumed to be asymptomatic because authors stated that these were screening patients and hematochezia part of exclusion criteria 
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Table 4. Definitions of clinical importance of extracolonic findings 
Author (Year) Definition for Clinical Importance of ECFs 
Gluecker et al. (2003) 
 
- High importance: requiring surgical treatment, medical intervention and/or further investigation during that patient care visit 
- Medium importance: did not require immediate treatment but would likely require investigation, recognition or treatment at a later time  
- Low importance: benign and unlikely to require further medical treatment or additional workup 
 
Chin et al. (2005) 
 
- Clinically relevant: "required medical or surgical attention, or further hematological, biochemical, and/or radiological investigation after 
assessment of several factors..." including "the patient's medical history and prior investigations taken, the radiological appearance of the 
CT findings, and the relevance of these findings in the current clinical context of the patient." 
- Non-clinically relevant: those judged not clinically relevant did not have further diagnostic testing or new treatments initiated 
 
Flicker et al. (2008) 
 
- C-RADs classification
a
 
- E3 and E4 lesions further classified into three categories: (1) previously imaged, (2) additional imaging (performed to evaluate CTC 
finding) and (3) received no subsequent workup 
 
Pickhardt et al. (2008) 
 
- Moderate or greater potential importance: need for further workup or, when CTC is diagnostic, findings considered moderate or greater 
clinical importance (authors stated that these corresponded to E3 or E4 C-RADS findings) 
- Minimal or no potential importance: no need for further workup or, when CTC is diagnostic, findings considered low clinical 
importance 
 
Veerappan et al. (2010) 
 
- C-RADs classification
b
 
- Classified high-risk lesions as those discovered to be a malignancy on the basis of pathologic findings or a large abdominal aortic 
aneurysm (≥ 5 cm) confirmed in the operating room 
 
Macari et al. (2011) 
 
- C-RADs classification
a
 
 
 
a
 C-RADS classification system (provided in Table 1) applied retrospectively 
b
 C-RADS classification system (provided in Table 1) applied retrospectively for scans performed before January 1, 2006 and prospectively after January 1, 2006 
  
- 45 - 
 
Table 5. Primary outcomes 
Author (Year) 
Follow-up 
Duration 
Excluded 
Previously 
Detected ECFs? 
Frequency of 
Incidental 
Findings and 
total # of ECFs 
Frequency of High 
Clinical Importance 
Findings
a
 
Frequency of 
Moderate or High 
Clinical Importance 
Findings
b
 
Imaging 
Performed or 
Recommended 
(%ECFs & Total) 
%ECFs 
Needing 
Surgery 
Chin et al. (2005) 
2 years after 
CTC 
Yes
c
 
 
27.2% (118 of 432 
subjects) 
 
146 ECFs in 118 
subjects (avg. 1.2 
ECFs/subject) 
 
7.4%  
(32 of 432 subjects)
d
 
NR
d
 
All ECFs: 21.2% 
(31 of 146) 
 
High imp: 96.9% 
(31 of 32) 
0% 
Pickhardt et al. 
(2008) 
Avg. 18 mos. 
(range 3 mos.-24 
mos.) 
Yes 
NR 
 
# ECFs not reported 
NR 
 
8.6%  
(189 of 2195 subjects) 
All ECFs: NR
e
 NR
f
 
Flicker et al. 
(2008) 
E3 lesions: 
avg. 26 mos. 
(range 9-76 
mos.) 
 
E4 lesions: 
avg. 18 mos. 
(range 20 days-
48 mos.) 
No (but reported 
separately) 
NR
g
 
 
All subjects 
combined: 72.5% 
(272 of 376 subjects) 
 
All subjects 
combined: 520 ECFs 
in 272 subjects (avg. 
1.9 ECFs/ subject) 
2.9%  
(6 of 210 subjects) 
17.1%  
(36 of 210 subjects) 
All ECFs: NR
g
 
 
E3 & E4: 35.5% 
(11 of 31) 
 
E4: 100% 
(5 of 5) 
NR
h
 
 
NR: Not reported 
a
 Clinical importance defined by study author, some prospectively based on the lesion’s characteristics and some retrospectively based on the final diagnosis. For 
studies using C-RADS, I reported frequency of patients with E4 findings. See Table 4 above for definitions. 
b
 For studies using C-RADS, I reported combined frequency of patients with E3 or E4 findings. 
c
 Included previously detected ECFs with significant change 
d
 No separate category for moderate significance findings (see Table 4 above) 
e
 Number of ECFs not reported. 7.2% (157 of 2195) had workup recommended by radiologist and 5.2% (115 of 2195) completed recommended workup 
f
 Total of 22 surgeries reported 
g
 Not reported for the separate analysis for asymptomatic patients with average risk of colorectal cancer 
h
 Only reported surgeries that might have resulted in benefit, which included 1 AAA repair and 2 partial nephrectomies for renal cell carcinoma 
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Table 5. Primary outcomes (continued) 
Author 
(Year) 
Follow-up 
Duration 
Excluded 
Previously 
Detected ECFs? 
Frequency of 
Incidental 
Findings and 
total # of ECFs 
Frequency of High 
Clinical Importance 
Findings
a
 
Frequency of 
Moderate or High 
Clinical 
Importance 
Findings
b
 
% ECFs with 
Imaging 
Performed or 
Recommended 
% ECFs 
Needing Surgery 
Gluecker et 
al. (2003) 
At least 12 mos. 
(range 401-
1513 days) 
No 
68.9% (469 of 681 
subjects) 
 
858 ECFs in 469 
subjects (avg. 1.8 
ECFs/subject) 
10.4%  
(71 of 681 subjects) 
37.3%  
(254 of 681 
subjects) 
All ECFs: 12.8% 
(110 of 858) 
 
High/Mod Imp: 
56.1% 
(110 of 196) 
 
High Imp: 98.9% 
(87 of 88) 
All ECFs: 1.3%  
(9 of 858) 
 
High/Mod Imp: 
4.6% 
(9 of 196) 
 
High Imp: 9.1%  
(8 of 88) 
Macari et al. 
(2011) 
NR NR 
55.4% (113 of 204 
subjects)
c
 
 
# ECFs: NR 
NR 
4.4%  
(9 of 204 subjects) 
NR NR 
Veerappan et 
al. (2010) 
Mean 19.5 mos. 
(range 6 mos.-4 
yrs.) 
No (but reported 
separately) 
45.5% (1037 of 
2277 subjects) 
 
# ECFs: NR 
1.5% 
(35 of 2277 subjects)
d
 
10.1% 
(230 of 2277 
subjects)
d
 
All ECFs: NR 
 
E3 & E4:86.1% 
(198 of 230) 
 
E4: 88.6% 
(31 of 35) 
 
All ECFs: NR 
 
E3 & E4: 8.3% 
(19 of 230) 
 
E4: 34.3% 
(12 of 35) 
 
NR: Not reported 
a
 Clinical importance defined by study author, some prospectively based on the lesion’s characteristics and some retrospectively based on the final diagnosis. For 
studies using C-RADS, I reported frequency of patients with E4 findings. See Table 4 above for definitions. 
b
 For studies using C-RADS, I reported combined frequency of patients with E3 or E4 findings 
c
 Separate analysis for younger cohort since this group fit into the inclusion criteria for age distribution 
d This is excluding previously detected extracolonic findings 
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Table 6. Summary of high clinical importance extracolonic findings 
    Early stage cancers (All cancers)  
Study Author N 
Total ECFs/High 
clinical importance 
ECFs (%) 
AAAs Ovary Lymphoma Lung Kidney Liver Pancreas Gallbladder Bladder Other 
Chin et al. (2005) 432 27.2% / 7.4% 5
a
 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Pickhardt et al. 
(2008) 
2195 NR / NR ?
b
 ? (0) ? (3) ? (1) ? (3) ? (0) ? (0) ? (0) ? (0) ? (2)
c
 
Flicker et al. (2008) 
527  
(210 avg. 
risk) 
NR / 2.9% ?
d
 ?
 e
 ?
 e
 ?
 e
 ?
 e
 ?
 e
 ?
 e
 ?
 e
 ?
 e
 ?
e
 
Gluecker et al. 
(2003) 
681 68.9% / 10.4% 4 ? (3) ? (0) ? (1) ? (2) ? (0) ? (0) ? (0) ? (0) ? (0) 
Macari et al. (2011) 204 55.4% / NR ? ? ? ? ? ? ? ? ? ? 
Veerappan et al. 
(2010) 
2277 45.5% / 1.5% 2 0 (0) 0 (1) 1 (2) 2 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 
NR: Not reported 
a
 Reported 6 AAAs were diameter 2.8-4.5 cm. I defined AAAs as greater or equal to 3 cm but the study did not report each individual size meaning the actual 
figure could be 5 or less AAAs.
 
b
 Reported 12 aneurysms in the aortoiliac system 
c
 Other: 2 abdominal metastatic cancer 
d
 Among all (average- and high-risk) subjects, they reported 1 new AAA 
e
 Among all (average- and high-risk) subjects, they reported 3 confirmed cancers (metastatic ovarian and 2 RCC)  
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Table 7. Summary of potentially clinically important extracolonic findings 
Study Author N 
Total ECFs/High 
clinical importance 
ECFs (%) 
Liver 
solid 
mass 
Lung 
nodule 
Kidney 
solid 
mass 
Adrenal 
nodule 
Pancreatic 
solid  mass 
Pancreatic 
cystic mass 
Ovarian 
cystic or 
complex 
mass 
 
Enlarged 
lymph nodes 
Other 
Chin et al. 
(2005) 
432 27.2% / 7.4% 0 0 0 0 0 0 0 0 0 
Pickhardt et 
al. (2008) 
2195 NR / NR ? ? ? ? ? ? ? ? ? 
Flicker et al. 
(2008) 
527 
(210 avg. 
risk) 
NR / 2.9% ?
a
 ?
a
 ?
a
 ? ? ? ?
a
 ? ?
b
 
Gluecker et al. 
(2003) 
681 68.9% / 10.4% 2 26 ?
c
 0 0 1 6 2 6
d
 
Macari et al. 
(2011) 
204 55.4% / NR ? ? ? ? ? ? ? ? ? 
Veerappan et 
al. (2010) 
2277 45.5% / 1.5% 0 4 15 1 1
e
 1
e
 7 3 1
f
 
 
a
 Among all (average- and high-risk) subjects, reported 6 lesions suspicious for malignancy (2 solid renal lesions, 1 solid liver lesion, 1 lytic bone lesion, 1 ovarian 
mass and 1 lung nodule > 2 cm) 
b
 Other: 1 lytic bone lesion
  
c
 Did not report solid kidney masses specifically, but did report 34 kidney masses 
d
 Other: 1 low-attenuation liver lesion and 5 cystic liver lesions 
e
 Only one pancreatic mass – did not report if it is solid or cystic 
f
 Other: 1 retroperitoneal mass  
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Table 8. Required Workup for ECFs  
Study Author N 
Total ECFs/High 
clinical importance 
ECFs (%) 
Total 
N
a
 (%) 
US CTs MRIs X-rays PET scans Surgeries 
Non-surgical 
Invasive 
Procedures 
Medical 
Tx 
Chin et al. 
(2005) 
432 27.2% / 7.4% 
32 
(7.4%) 
26 10 0 1 1 0 0 0 
Pickhardt et 
al. (2008) 
2195 NR / NR 
133 
(6.1%) 
64 59 11 10 2 22 19 ? 
Flicker et al. 
(2008) 
527 
(210 avg. 
risk) 
NR / 2.9% 
6 
(2.9%) 
?
b
 ?
 b
 ?
 b
 ?
 b
 ?
 b
 ?
 b
 ?
 b
 ?
 b
 
Gluecker et al. 
(2003) 
681 68.9% / 10.4% ? 46 41 0 12 0 8 ?
c
 2 
Macari et al. 
(2011) 
204 55.4% / NR 
4 
(2.0%) 
4 5 0 0 0 ? ? ? 
Veerappan et 
al. (2010) 
2277 45.5% / 1.5% 
199 
(8.7%) 
57 182 13 9 10 18 2 ? 
 
a
 The total number of patients receiving some type of workup 
b
 Not reported separately for asymptomatic, low-risk subjects. Workup for all subjects included: 8 US, 9 contrast-enhanced CTs, 1 abdominal X-ray and 3 
surgeries (only selected surgeries reported) 
c
 Specific number not reported, but authors stated that many patients received treatment for renal and bladder calculi 
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Discussion: 
Frequency of Extracolonic Findings 
The included studies reported overall frequencies of extracolonic findings (ECFs) ranging 
from 27.2% to 68.9% (mean 49.3%). Combining study populations, 1737 of 3594 subjects 
(48.3%) had at least one ECF. Studies including patients with a personal history of polyps, a 
polyposis syndrome or a family history of colorectal cancer reported higher rates of ECFs. These 
results provide further support for the finding that risk of colorectal cancer is related to the 
frequency of ECFs, which was previously noted by Pickhardt et al.
1
 This finding could have 
important implications for clinical practice, as the balance of benefits to harms and the cost-
effectiveness might be different for screening and surveillance populations. 
There are several other important factors in the reported frequencies of extracolonic 
findings. For instance, one excluded study
83
  reported that their older cohort (mean age = 69.2 
years) had a significantly higher percentage of extracolonic findings than the remaining 
screening population (mean age = 56.9 years). Subjects with comorbid diseases also had a higher 
frequency of ECFs.
84
 These findings might be related, since older patients are more likely to 
have comorbidities. There are a few potential explanations for these findings. It is possible that 
older individuals are more likely to develop lesions that can be discovered on CT scans. 
Alternatively, radiologists might be more prone to identify or report such lesions for older 
patients. 
Differences in radiologist practice and experience might also contribute to differences in 
ECF frequency. For instance, Chin et al.,
84
 who reported the lowest frequency of ECFs, 
employed two CTC readers. The study with the next lowest frequency
60
 used an experienced 
radiologist to review scans with significant findings. Conversely, only one reader interpreted the 
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CTC scans in the two studies with the highest reported frequencies of ECFs.
33,86
 These findings 
support the fact that employing a second radiologist reduces the rates of false-positives. 
However, it is also possible that employing two radiologists could increase false negatives. Two 
studies in this review
33,85
 collected information on lesions missed during the initial CTC. One of 
these studies
85
 found 144 E2, 29 E3 and 4 E4 lesions that were previously unreported, resulting 
in an 8.8% miss rate per patient. The other study
33
 reported that 44 lesions (3 high importance, 
20 medium importance, 21 low importance) were missed on the initial radiological exam (25%) 
or found on subsequent radiological follow-up (75%). 
Radiologist experience could also played a role, as studies report that more experienced 
radiologists are less likely to recommend additional imaging.
63
 This review’s results did little to 
strengthen or weaken this claim. In addition, unimportant (i.e. E2 and below) lesions might have 
higher variation since some radiologists choose not to report these findings. A previously-
published review stated that 58% of surveyed research practices reported all extracolonic 
findings while the remaining 42% only reported significant lesions.
5
 Another factor that could 
greatly affect ECF frequency is whether previously diagnosed ECFs are included. This is an 
important consideration since most physicians are only interested in finding previously 
undiagnosed lesions with CTC. One study
33
 combined previously detected and newly diagnosed 
extracolonic findings. Not surprisingly, this study reported the highest frequency of ECFs. 
My results provide no clear indication that CTC parameters, such as varying radiation 
dose or slice thickness, played a role in the observed differences in ECF frequency. Previous 
studies
2
 have raised the possibility that smaller slice thickness and higher radiation doses might 
increase the frequency of ECFs. However, there are several confounding factors that make it 
difficult to determine the importance of slice thickness and radiation dose. 
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Classification of Clinical Importance 
 The six included studies either employed the C-RADS classification system or a similar 
system based on the likelihood of additional workup. Despite the similarities of these systems, 
there was considerable variability in the number of clinically important findings and the 
recommended workup. Based on the results of this review, it appears that these classification 
systems do little to reduce clinical variability, as they set out to accomplish. Therefore, poor 
dissemination of these classification systems among radiologists might not be the primary source 
of clinical variability. In addition, these systems do not appear to classify lesions based on their 
likelihood of improving patient outcomes. The classification systems might benefit from 
validation studies that could properly assess their likelihood of providing accurate prognostic 
information to patients. 
 
Frequency of Clinically Important ECFs 
Studies reported that 1.5% to 10.4% (mean 5.6%) of subjects had at least one finding of 
high clinical importance. Combining the populations, a total of 144 out of 3600 subjects (4.0%) 
had at least one high-importance finding. Studies reported that the frequency of subjects with at 
least one moderate or high importance lesion ranged from 4.4% to 37.3% (mean 15.5%). In total, 
230 out of 2277 subjects (10.1%) had a moderate- or high-importance lesion. 
Many of the same factors that contributed to the variability in the overall frequency of 
ECFs likely influenced the number of high importance findings reported. However, one of the 
biggest contributors to variability is the inconsistency of radiologists reviewing CTCs. The C-
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RADS classification system was developed to reduce the variability of these findings, but there 
are three major reasons that classification systems might not significantly reduce this variability. 
First, there might be inadequate dissemination of guidelines. In fact, a national survey 
reported that many radiologists are unaware of the published recommendations on CTC.
69
 
However, most studies in my review employed similar classification systems and employed 
trained radiologists. Therefore, poor dissemination of recommendations does not explain the 
large variability seen in my review. 
The second possibility is that classification systems do not provide enough guidance for 
some extracolonic lesions. As shown in Table 1, the C-RADS classification system provides 
little guidance for determining the clinical significance of a lung nodule and does not mention 
skeletal lesions at all. In addition, the C-RADS system might be more helpful when paired with 
additional clinical guidance for working up ECFs, such as the White Paper published by the 
ACR’s Incidental Findings Committee.89 
Third, even with clear classification systems, inter-rater variability might remain. This is 
the most likely explanation for the variability seen in my study. Radiologist inter-rater variability 
is already well described in the literature. One randomized controlled trial of 50 asymptomatic, 
average-risk patients assigned half these patients to receive total-body scanning with CT and the 
other half to be followed clinically.
90
 Two experienced specialty radiologists, including 2 
abdominal radiologists, were provided guidelines on the clinical classification and workup for 
specific lesions. Of the subjects receiving CT scans, 64% (16 out of 25) had incidental findings. 
The radiologists disagreed on 9 of these 16 findings (κ = 0.52), corresponding to moderate 
agreement. While the full-body CT is not entirely comparable with CT colonography, this study 
identifies the potential for large practice variation even when clear guidelines are provided to 
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radiologists. It is possible that improved training, specifically on interpreting ECFs, could reduce 
some of this variability. In fact, experience in community CTC screening programs shows that 
experience alone is not a proper substitute for CTC-specific training.
64
 
 
Reported AAAs and Extracolonic Malignancies 
I also collected information on hard outcomes such as AAAs and extracolonic cancers, in 
order to circumvent the variability between classification systems and determine how many how 
many highly-important findings might benefit from early intervention. Studies reported that 
0.09-1.2% of subjects were diagnosed with AAAs. Among the three studies reporting these 
outcomes, AAAs represented 8.6% of high importance findings. Of these 12 newly diagnosed 
AAAs, 4 (33.3%) required surgical repair during the reported follow-up period. 
It is difficult to estimate the balance of benefits and harms from detecting AAAs from 
screening CTC, but previously published analyses provide some clues. According to estimates 
from the USPSTF, approximately 500 men aged 65 to 74 who are current or former smokers 
would need to be screened to prevent 1 AAA-related death. Among never-smokers of the same 
age range, approximately 1,800 would need to be screened to prevent 1 AAA-related death.
91
 CT 
colonography is unlikely to provide additional diagnostic accuracy, as ultrasonography has a 
reported sensitivity of 95% and specificity of 100% for AAAs. 
The potential benefits of screening for AAAs are more limited for women age 65 to 75, 
since their risk of AAA rupture is much smaller. In addition, the size of the screen-detected AAA 
has an influence on the balance of benefits and harms. For instance, little evidence supports 
benefits of surveillance or surgery for small AAAs (diameter 3-3.9 cm). The benefits of surgical 
repair are more pronounced for older patients with large AAAs (diameter ≥ 5.5 cm). One study 
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reported that surgery for older patients with large AAAs resulted in an estimated 43% reduction 
in AAA-related mortality, although no improvement in all-cause mortality.
75
 Only one study in 
my review
60
 included a separate category for high-risk AAAs (≥ 5 cm), reporting that 1 out of 
the 2 newly-diagnosed AAAs were high-risk. Therefore, I cannot conclude how many AAAs 
detected from screening CTCs are likely to have benefitted from detection and intervention. 
Another important factor to consider is the frequency of screening for AAAs. Several 
studies have reported that the incidence of new AAAs in a period of ten years ranges from 0-4%. 
Furthermore, none of these incidental AAAs were larger than 4 cm in diameter, meaning they 
were less likely to benefit from early intervention.
92-95
 Based on this evidence, it is unlikely that 
subsequent CTC exams would increase the number of high-risk AAAs detected. There are also 
potential harms of finding AAAs from screening, which were not addressed in the included 
studies. Open surgical repair of AAAs carries a 4-5% mortality and results in complications (e.g. 
myocardial infarction, respiratory complications, spinal cord ischemia and graft infection) for 
approximately one-third of surgical patients. Endovascular repair of AAAs, which has become 
increasingly popular, might have a lower risk of complications but also has less certain long-term 
effectiveness.
75
 There are also potential psychological harms of screening for AAAs. For 
instance, one study reported significant decreases in quality of life scores for patients with AAAs 
receiving follow-up tests.
96
 The same decreases in quality of life were not seen in a control group 
without AAAs. Unfortunately, no studies included in my review explored the possibility of 
psychological outcomes of being diagnosed with or receiving surveillance for an abdominal 
aortic aneurysm. 
My included studies report that 0.23-0.88% of subjects were diagnosed with cancers and 
roughly a quarter of these lesions were early-stage cancers. Renal cell carcinoma (RCC) is the 
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cancer with the most robust evidence suggesting potential benefit from its incidental discovery. 
The incidence of renal cell carcinoma has increased dramatically with the rise of cross-sectional 
imaging and approximately 60% of RCC cases are detected incidentally. However, despite the 
drastic rise in its detection, the mortality rates for RCC have been steady over the past few 
decades.
89
 One explanation for these trends is that many of these cancers would not have 
otherwise caused important symptoms (i.e. they represent overdiagnosis).
97,98
 Some evidence 
supports the potential for overdiagnosis of RCC. For instance, while only 0.5% of individuals die 
from RCC, this cancer is detected in up to 2% of autopsies.
89
 Another study investigating the 
progression of renal tumors reported that 14% regressed in size and 40% grew at such a slow rate 
that it would take more than six years for them to double in size.
99
 They also reported that slow 
growing tumors were more common in elderly patients. Based on this evidence, of the 9 renal 
cancers reported in this review, it is likely that some would not have presented clinically during a 
patient’s lifetime. As a result, some of these patients might have experienced surgery 
unnecessarily. In addition, even those that would have otherwise presented clinically might not 
have benefitted from early treatment. On the other hand, it is possible that some of these patients 
received benefits from early detection and intervention. Unfortunately, there is no way to 
determine which incidentally-detected RCCs are indolent and which are aggressive. 
The screening CTC studies included in my review also reported 3 confirmed ovarian 
carcinomas and several lesions suspicious for ovarian cancer. Again, it is impossible to 
determine the exact balance of benefits and harms for women with incidentally-detected ovarian 
cancers. However, current evidence does not indicate that screening for ovarian cancer improves 
patient outcomes. The largest RCT to-date on this topic is the Prostate, Lung, Colorectal and 
Ovarian (PLCO) Cancer Screening Trial. In this study, investigators randomly assigned 78,216 
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average-risk women to screening for ovarian cancer with CA-125 and transvaginal ultrasound or 
usual care.
100
 After 13 years of follow-up, the two groups showed no differences in the stage of 
diagnosed ovarian cancer or the death rate from ovarian cancer. Conversely, there is more 
evidence on the harms of screening for ovarian cancer, including the risks of false-positives and 
complications from the resulting workup. For instance, one-third of the women with false-
positives in the PCLO trial underwent oophorectomy.
100
 In the entire screening group, there were 
20 surgeries performed for every screen-detected ovarian cancer and approximately 20% of these 
surgeries resulted in some complication. The potential for false-positive ovarian lesions was also 
demonstrated in my review. One study
82
 included in this review reported that all 10 surgeries for 
adnexal lesions revealed benign findings. Another study
60
 reported that CTC revealed incidental 
ovarian lesions that led to 8 surgeries, all of which revealed benign masses. 
My included CTC studies only reported a few diagnoses of lung cancer. Based on the 
recent randomized controlled trial,
101
 which reported a 20% reduction in mortality, it is possible 
that some benefit might arise from discovering incidental lung lesions. However, the reported 
benefits of screening for lung cancer were found among a highly-selected group of individuals 
aged 55 to 74 with at least a 30 pack-year history of smoking. In addition, these benefits were 
coupled with severe potential harms, including the deaths of 16 patients (6 of whom did not have 
lung cancer) within 60 days of the invasive diagnostic procedure. Therefore, it would be harder 
to justify the large harms of this screening in the broad population of adults age 50-74 receiving 
screening CTC. Screening for other cancers, including those of the pancreas, bladder and adrenal 
glands, is likely to provide minimal benefit at best, if not result in some net harm to patients. 
Despite the paucity of supporting evidence for population-wide screening for AAAs and 
extracolonic cancers, it is likely that the vast majority of benefit from detecting ECFs during 
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screening CTC come from finding these two groups of lesions. However, these two lesions 
represent a minority of findings deemed to be of high clinical importance. This suggests that my 
classification systems are too sensitive, picking up too many benign findings that lead to 
unnecessary and potentially harmful workup. Sliding down the receiver operating characteristic 
(ROC) curve to decrease sensitivity and increase specificity might improve the cost-effectiveness 
of CTC and improve patient care. This could be accomplished by limiting the reporting of 
extracolonic lesions to AAAs and high-yield extracolonic cancers. Hassan et al.
102
 suggested a 
similar approach in their cost-effectiveness analysis of CTC by only looking for intracolonic 
lesions, AAAs and extracolonic cancers. But, in this analysis, detecting extracolonic cancers 
contributed only 2% to life-years gained (LYG) but 55% of the costs of CTC. This equates to 
$1.5 million per LYG, likely well above the expense considered to be cost-effective.
103
 The cost-
effectiveness of AAAs was much better, accounting for 16% of LYG while contributing only 6% 
to the overall costs. However, many organizations, including the USPSTF, already recommend 
one-time screening for AAAs with ultrasound for older men who have ever been smokers.
91
 
Based on the evidence, the survival benefits of AAA screening are greatest for older males who 
are former or current smokers. In addition, the evidence suggests limited effectiveness of repeat 
screening for AAAs. Thus, the majority of life years will be gained during the first CTC, with 
large drop-offs in benefit for subsequent CTCs. Furthermore, the psychological harms of 
screening (e.g. anxiety), however small, are likely to occur for each round of screening. 
Therefore, while there are likely mortality benefits from detecting AAAs with screening CTC, 
this approach might not provide an optimal ratio of benefits to harms or maximize cost-
effectiveness. In fact, the cost-effectiveness analysis by Hassan et al.
102
 compared screening CTC 
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to optical colonoscopy alone, without considering the alternative of one-time screening with 
ultrasonography. 
To account for the number of findings that might eventually be diagnosed as cancer, I 
reported the number of lesions suspicious for cancer. Unfortunately, only three studies reported 
the numbers of such lesions and these studies had huge variability in follow-up and reporting. 
Chin et al.
84
 only reported the final diagnoses and thus had no lesions suspicious for malignancy. 
Veerappan et al.,
60
 on the other hand, listed all initial CTC interpretations of ECFs in addition to 
their final diagnoses, reporting 32 lesions suspicious for malignancy among 2277 subjects. 
Another reported 43 suspicious lesions among 681 subjects. The majority of reported lesions 
were found in either the lungs or kidneys. The imprecision in these numbers makes it difficult to 
estimate the percentage of screening CTC patients who might develop cancer after the study 
follow-up period. In addition, most of these lesions will be false positives meaning a minority are 
likely to represent truly clinically important findings. For instance, a recent study stated that 
approximately 24 of 25 lung nodules detected during screening with low-dose CT were false-
positives.
101
  
 
Clinical Workup of ECFs 
 Among all studies of screening CTC, approximately 1 in 20 subjects required some 
clinical workup. This number likely underestimates the true frequency of clinical workup as 
many studies focused solely on radiological workup or workup performed at their institutions. In 
the three studies that reported surgeries and invasive procedures in addition to radiological 
workup, roughly 1 out of every 14 subjects required some clinical workup. 
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 Since many studies did not report clinical workup or only reported selective outcomes, a 
more accurate range might be provided by the frequency of moderate/high and high-clinical 
importance findings. According to the C-RADS classification system, E4 (high importance) 
lesions require immediate workup or intervention while E3 (moderate importance) findings 
sometimes require workup, depending on local practice and patient preference. E2 findings and 
below require no workup or intervention, by definition. Using these assumptions, the frequency 
of subjects requiring some clinical workup falls somewhere between 5.5% and 15.5%. In other 
words, 1 out of every 6 to 18 subjects receiving screening CTC will require some clinical work-
up. 
The relative frequency of final diagnoses and suspicious lesions in these studies is likely 
to be influenced by the length of follow-up and whether the study was retrospective or 
prospective (reported in Table 5 above). For instance, Veerappan et al.
60
 performed an extensive 
retrospective review of patient’s records to determine a final diagnosis for the majority of 
suspicious lesions found on screening CTC. Conversely, Macari et al.
86
 did not report the length 
of follow-up and were unable to locate several electronic medical records, which was their lone 
source of information for clinical workup. 
Paradoxically, some of the factors that increase the frequency of ECFs might reduce the 
chance of receiving some clinical workup. For instance, in the study looking at the effect of age 
on CTC results,
83
 only 50.6% of the older cohort with an ECF received workup compared with 
57.3% in the general screening population. Similarly, Chin et al.
84
 reported that while patients 
with comorbidities were more likely to have an ECF discovered on the initial CTC, they were 
much less likely to receive clinical follow-up. Physicians might be less willing to perform further 
testing on older populations that are more likely to have comorbidities. This may be because 
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some of these patients would be unable to tolerate an invasive procedure or surgery. Moreover, 
physicians could be aware that an older and sicker population is more likely to die from causes 
other than their ECF, even if it represents a serious diagnosis like an extracolonic cancer. In other 
words, older and sicker populations, which have higher frequencies of ECFs, are more likely to 
be overtreated. This claim is strengthened by the finding that slow-growing cancers are more 
likely to be found in older individuals.
99
 
 
Comparison to Previous Publications on this Topic 
My findings are similar to the existing literature on extracolonic findings from CTC. The 
last systematic review on this topic,
4
 which looked at both screening an diagnostic CTC, reported 
that 58% of subjects (range 12%-90%) had at least one incidental lesion and 13.8% of subjects 
received some clinical workup. This review noted that only 0.8% of patients required immediate 
treatment and 3.7% were diagnosed with an extracolonic cancer or AAA. Nearly half (42%) of 
the reported cancers in their review were early-stage (N0M0). 
The total number of patients with extracolonic findings was likely greater than my 
systematic review because the authors combined symptomatic and asymptomatic populations. 
Their review only included three studies with “screening” populations and one of these three104 
included patients with a personal history of colorectal cancer. Furthermore, the review was 
published the same year as the C-RADS classification system, making it impossible to assess 
how the system might affect clinical practice. Thus, my review adds to their findings by 
suggesting a slightly lower frequency of ECFs in true screening populations and providing 
evidence that a standardized classification system might not be particularly effective at reducing 
variability in the frequency and clinical importance of ECFs.  
- 62 - 
 
 
Implications of Results for Clinical Practice 
There is little evidence in this review supporting the claims that detecting extracolonic 
findings during screening CTC improves patient outcomes. Some organizations have come to a 
similar conclusion and have not endorsed CTC for colorectal cancer.
73
 In regards to ECFs 
specifically, screening with abdominal imaging is not currently supported by the evidence and is 
not recommended by the American College of Radiology.
105
 Furthermore, if such screening did 
have clear net benefits, it would be most effective with IV-contrast and higher radiation doses. 
Therefore, the claimed benefits of detecting extracolonic findings from screening CTC, which 
uses low radiation doses and no IV contrast, should be interpreted with caution. 
Currently, with the medicolegal concerns and reporting requirements for 
reimbursement,
106
 the debate is not whether to report extracolonic findings but how to report 
extracolonic findings. One option would be selective reporting of incidental lesions, focusing on 
lesions with the greatest potential benefit such as high-risk AAAs and select extracolonic 
cancers. Still, the current medical culture in the United States might prohibit such withholding of 
information. At very least, radiologist might consider a move towards not reporting findings that 
do not require any workup (i.e. lesions of C-RADS E2 or below), as suggested by the Working 
Group on Virtual Colonoscopy.
3
 In addition, primary care physicians should try to limit clinical 
workup to findings that might benefit from early intervention and report only potentially 
important findings to patients. 
In addition, physicians should inform patients who opt for screening CTC of the 
likelihood of extracolonic findings, the potential for additional workup and the possible benefits 
and harms of such a workup. Given the complexity of concepts such as overdiagnosis and the 
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prevailing belief in the benefits of early detection, the discussion of harms might warrant more 
time and attention. Patients must be able to comprehend the benefits and harms of finding ECFs 
before they can make truly informed decisions. 
One change that might reduce the variability of ECFs and decrease the number of 
unnecessary workups is a requirement for ECF-specific training for radiologists. Currently, the 
recommended training focuses on correctly interpreting a specific number of pathology-
confirmed colorectal cancers,
87
 with no specific training requirements for extracolonic lesions. 
Several studies support the benefits of existing CTC training requirements on the sensitivity and 
specificity of detecting colorectal cancers.
107
 It is possible that similar training for ECFs would 
reduce unnecessary surveillance and treatment. 
Moreover, classification systems and recommendation statements do not appear to 
provide ample guidance on the type and method of working up specific extracolonic findings. 
These studies showed huge variability in how extracolonic findings were worked up. Currently, 
the C-RADS classification system provides no guidance on how to address these findings other 
than stating which ones require some workup. The ACR’s Committee on Incidental Findings 
provides a bit more information on how to address specific extracolonic findings by suggesting 
radiographic follow-up for specific findings. Unfortunately, their recommendations still fall short 
in many ways. For instance, in their section on low-dose, non-contrast CT they do not address 
lesions of the lungs, ovaries or bone.  
Lastly, classification systems do not categorize lesions based on the likelihood of net 
benefit from workup and treatment. For instance, findings with some evidence supporting 
benefits for their screening, such as AAAs and renal cell carcinomas, are grouped together with 
incidental lesions that are less likely to benefit from workup and treatment. In addition, there is 
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reason to question the ability for classification labels to provide accurate prognostic information. 
The guidelines from the ACR and Virtual Colonoscopy Working Group might therefore benefit 
from proper validation. Lastly, the reported variability among included studies that employed C-
RADS raises questions about its reliability. 
 
Limitations of the Literature 
 The literature on extracolonic findings from screening CTC suffers from several 
weaknesses. 
First, many studies had poor follow-up of ECFs and incomplete reporting of outcomes. 
Several studies decided not to report on the clinical workup for E1 or E2 findings since C-RADS 
dictates that they should not require follow-up. However, such an approach risks introducing bias 
into estimations. First, lesions determined to be of low clinical importance by the study authors 
might be followed in other settings, such as community hospitals. Therefore, the reported 
workup required for ECFs might be an underestimate. In fact, Pickhardt et al.,
82
 who followed all 
ECFs, reported that 18 subjects received unnecessary workup for findings deemed to be less than 
moderate importance. These findings show that unnecessary workup might occur in the more 
controlled settings of a clinical study. It is possible that these rates would be even higher in 
community settings, where less experienced radiologists might be unfamiliar with the guidelines 
for addressing ECFs. In addition, excluding the workup for E1 and E2 findings assumes that the 
radiologists correctly classified these findings during the initial CTC. It is possible that findings 
initially overlooked during the first CTC could require workup in the future. 
The poor follow-up of ECFs made it difficult to compare outcomes among studies, thus 
increasing the uncertainty of my conclusions. In order to reduce this variability in the future, 
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studies looking at screening CTC should use a set methodology for following ECFs. For 
instance, studies should report all workup including radiological exams, clinical visits, surgical 
procedures, invasive tests and medical treatments. Studies should also investigate the 
complications and psychological effects of this workup. The psychological effects could be 
beneficial (e.g. relief from a workup that reveals a benign lesion) or harmful (e.g. anxiety and 
uncertainty from a workup that might reveal a life-threatening diagnosis). Lastly, studies should 
report who initiated specific aspects of the workup for incidental lesions. For instance, it would 
be helpful to know what aspects of the workup are managed by radiologists or primary care 
physicians so that practice guidelines can be directed to relevant groups. 
These studies collected little information on the potential harms of being diagnosed with 
incidental findings. For instance, there is the considerable risk of false positives. False positives 
come with potential psychological harms (e.g. anxiety) and physical harms of the resulting 
workup (e.g. ionizing radiation from CT or complications from invasive diagnostic procedures). 
These same psychological and physical harms are also experienced by those with true positives, 
although these patients have the possibility of clinical benefit. However, some of true positives 
likely represent overdiagnosis meaning that the resulting psychological and physical harms were 
experienced with no corresponding benefits. While the psychological harms could be more 
difficult to measure, they might be especially relevant for incidental findings that could result in 
years of diagnostic surveillance. There is sparse evidence on these harms, but some evidence 
suggests that they can be significant. One systematic review on the psychological impact of 
predicting individuals’ risk of illness reported that receiving a positive diagnosis is associated 
with a greater risk of depression, anxiety, poorer perceptions of health and psychological 
distress.
108
 
- 66 - 
 
Another weakness of the current body of literature is that no studies address how ECFs 
are addressed in community settings. All six of my included studies were performed in academic 
or military medical centers with highly experienced radiologists. In order to truly gauge the 
effects of widespread CTC, it will be important to determine the frequency and clinical 
implications of extracolonic findings in non-academic settings. It is possible that these areas 
might employ less experienced radiologists who are less informed of the guidelines on ECFs, 
leading to an increased frequency of incidental lesions and their subsequent workup.  
 
Limitations of Review 
This systematic review suffered from a few limitations. For instance, the decision to limit 
the review to screening populations reduced the number of included studies and might have 
weakened the strength of evidence. It was thought that focusing on a homogenous population 
might increase the precision of previous estimates on the frequency of ECFs, but my results were 
also widely variability. Nonetheless, I thought that it was important to focus on screening 
populations in order to provide better estimates for this group. This is especially important since 
the implications of ECFs are different for a screening population compared with symptomatic 
patients. In addition, my wide range of ECF frequencies among screening CTC studies 
strengthens the evidence that other factors (i.e. radiologist inter-rater variability) are primarily 
responsible for the existing variability. These sources of practice variability should be further 
explored before CT colonography becomes a first-line screening test for colorectal cancer. 
In order to increase the number of studies on asymptomatic populations in this review, I 
included studies that enrolled individuals at high risk of colorectal cancer. As a result, my study 
population might be less representative of a true screening population than a mixed 
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screening/surveillance population. This is especially relevant because my results indicated that 
patients at high risk of colorectal cancer had a higher frequency of ECFs. In addition, my review 
included studies from countries outside the United States. The only included non-US study
84
 was 
performed in Australia and did not differ greatly from other studies in terms of reported 
interventions or outcomes. 
Another weakness of my review is the inability to adjust for uneven follow-up periods, 
making it difficult to compare studies. The way I reported final diagnoses and workup set up an 
uneven comparison of studies, which have different times and methods of follow-up. Some 
studies performed an extensive, retrospective search of subjects’ medical records to determine 
diagnoses while others reported on selected outcomes. For instance, Flicker et al.
85
 followed only 
radiological workup, which might explain why they did not report the frequency of specific 
important diagnoses (i.e. AAAs, extracolonic cancers, etc.). I attempted to minimize the effects 
of these inconsistencies by excluding such studies from my calculated frequencies of specific 
diagnoses. However, it is possible that some of the studies that did report these outcomes also 
had poor follow-up. As a result, they might have underestimated the number of potentially 
serious diagnoses. This might not be an issue for AAAs, which can be diagnosed by screening 
CTC. But for extracolonic cancers, the length of follow-up might have a significant influence on 
the number of diagnosed cancers. To account for these differences, I also reported the number of 
lesions suspicious for malignancy. 
I had originally planned to develop an outcomes table following a hypothetical cohort of 
1,000 individuals receiving screening CTC. This table would report the expected number of 
ECFs, including moderate/high and high-importance findings, imaging tests, surgeries and 
medical treatments. In addition, it would lay out those findings that resulted in potential benefits, 
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potential harms or uncertain benefits/harms. But given the imprecision of results and the gaps in 
many reported outcomes, I were unable to develop such a table. 
 
Conclusions 
 In sum, about one-third of patients receiving screening CT colonography will have at 
least one extracolonic finding discovered. The likelihood of discovering an ECF is higher for 
patients at higher risk of colorectal cancer. Roughly 10% of subjects who receive screening CTC 
will receive a diagnosis of high clinical importance and nearly all of these will result in some 
clinical workup. Approximately 2% of all subjects will have an abdominal aortic aneurysm or 
extracolonic cancer, which might potentially benefit from early treatment. However, some of 
these diagnoses will not result in net benefits and the majority of subjects receiving clinical 
workup will be diagnosed with a benign lesion. 
 The certainty in these findings is reduced by the large variability between studies, which 
does not seem to be reduced by a universal classification system for clinical importance. Since 
2005, when the C-RADS system for classifying extracolonic findings was published, there has 
not been a reduction in the variability of reported ECFs or lesions of high-importance. Inter-rater 
variability between radiologists and inconsistent strategies for working up ECFs are likely the 
greatest contributors to the differences between studies. Increased radiologist training on 
correctly triaging ECFs might reduce some of the variability and unnecessary workup. In 
addition, selective reporting of outcomes that are more likely to benefit from workup (i.e. high-
risk AAAs and renal cell carcinomas) might improve the ratio of benefit to harm for patients 
receiving screening CTC. 
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Appendices: Methods 
 
Appendix A: Search Strategy 
Search Database Search Terms 
PubMed 
 
“(colonography[tw] OR virtual colonoscopy[tw] OR colography[tw] OR CT colonoscopy[tw] OR virtual 
endoscopy[tw]) AND (extracolonic[tw] OR incidental*[tw] OR incidentaloma*[tw] OR serendipitous[tw])” 
 
EMBASE 
 
“(Colonography:ti,ab,de OR “virtual colonoscopy”:ti,ab,de OR colography:ti,ab,de OR CT 
colonoscopy:ti,ab,de OR “virtual endoscopy”:ti,ab,de) AND (Extracolonic:ti,ab,de OR incidental*:ti,ab,de 
OR incidentaloma*:ti,ab,de OR serendipitous:ti,ab,de)” 
 
Cochrane Libraries 
 
“(Colonography OR “virtual colonoscopy” OR colography OR CT colonoscopy OR “virtual endoscopy”) 
AND (Extracolonic OR incidental* OR incidentaloma* OR serendipitous)” 
 
 
Appendix B: Reporting Criteria 
Category Criteria 
Description of Population 
 
Were the eligibility criteria well defined? 
 
Was recruitment well described, including: 
- Were patients enrolled consecutively? 
- How did investigators recruit patients (e.g. referral or self-selection)? 
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- From where were patients recruited? 
 
Was the population well-defined including information on subjects’: 
- Gender? 
- Ethnicity? 
- Previous history of polyps? 
- Risk factors for colon cancer (e.g. family history, polyposis syndrome)? 
- Present symptoms? 
 
Description of Interventions 
 
Were the interventions adequately described including: 
- Radiation dose 
- Slice thickness 
- Positioning of patient (i.e. supine and/or prone exam) 
- Use of IV contrast 
 
Description of Outcomes 
 
Were primary and secondary outcomes defined a-priori and clearly reported? 
 
 
 
Appendix C: Internal Validity Criteria 
Category Criteria 
Measurement Bias 
 
Equal: 
- Was there a standardized CTC technique used for all patients (i.e. radiation dose, 
slice thickness, use of IV contrast)? 
- Was the clinical importance of findings judged using a standardized 
classification system? 
Valid: 
- Were extracolonic findings clearly defined? 
- Were patients’ previously diagnosed extracolonic lesions excluded from the 
cohort? 
- Was the clinical importance of findings based on a classification system that was 
related to likelihood of gaining benefit from follow-up and/or treatment? 
Reliable: 
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- Did radiologists have adequate training to interpret CT colonography, according 
to the training guidelines published by the American College of Radiology 
(ACR)?
87
 
- Did another trained radiologist review scans? 
- If there were more than one observer (radiologist), did they independently assess 
scans? 
- Were radiologists blinded to past scan results during follow-up examinations? 
 
Selection Bias 
 
Are there any clear sources of selection bias? 
- Is there something that distinguishes those with extracolonic findings from those 
that don’t? 
- Are those who are lost to follow-up different from those who are left in the 
cohort? 
 
Confounding 
 
Is there something that distinguishes those with extracolonic findings from those that 
don’t? 
 
Lost to Follow-up/Dropouts 
 
Was more than 30% of the cohort lost to follow-up? 
 
Power 
 
Was the sample size < 50 subjects? 
 
 
Appendix D: External Validity Ratings – Adapted from the USPSTF78 
Rating Description 
Good 
 
The study differs minimally from the standard CT colonography screening population/situation/providers. It is 
highly probable (>90%) that the experience with CTC described in this study would be attained in a typical 
screening population. 
 
Fair 
 
The study differs in a few ways from the standard CT colonography screening population/situation/providers 
that has the potential to affect the clinical outcomes. It is moderately probable (50%-89%%) that the 
experience with CTC described in this study would be attained in a typical screening population. 
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Poor 
 
The study differs in many ways from the standard CT colonography screening population/situation/providers 
that has a high likelihood of affecting the clinical outcomes. The probability is low (<50%) that the experience 
with CTC described in this study would be attained in a typical screening population. 
 
 
 
Appendix E: Critical Appraisal Questions – Adapted from the USPSTF78 
1. Do the studies have the appropriate research design to answer the key question(s)? 
2. To what extent are the existing studies of high quality? (i.e., what is the internal validity?) 
3. To what extent are the results of the studies generalizable to the general US primary care population and situation? (i.e., what 
is the external validity?) 
4. How many studies have been conducted that address the key question(s)? How large are the studies? (i.e., what is the precision 
of the evidence?) 
5. How consistent are the results of the studies? 
6. Are there additional factors that assist us in drawing conclusions (e.g., presence or absence of dose-response effects; fit within 
a biologic model)? 
 
Appendix F: Strength of Evidence Grades 
Grade Description 
High 
 
Future research is unlikely to change the confidence of the evidence 
 
Moderate 
 
Future research will likely have an important effect on the confidence of this evidence and might 
change these estimates 
 
Low 
 
Future research will very likely have an important effect on the confidence of this evidence and is 
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likely change these estimates 
 
Very low 
 
The estimate provided is very uncertain 
 
 
 
Appendices: Results 
 
Appendix G. Internal Validity Ratings 
Aspects of Measurement Bias in Included Studies 
 
Author 
(Year) 
Equal Measurements Valid Measurements Reliable Measurements 
 
Standardized 
CT technique 
for all? 
Standardized 
system for 
clinical 
importance? 
Clinical 
importance 
based on 
dx/tx 
benefit? 
Previously 
diagnosed 
ECFs excluded 
or reported 
separately? 
Method of 
follow-up 
complete 
and 
accurate? 
Radiologists 
adequately 
trained for 
CTC? 
Duplicate 
reading of 
CTC scans? 
Review of 
CTC scans 
performed 
independently? 
Radiologists 
 blinded to 
patient 
history? 
Chin et al. 
(2005) 
Yes No No Yes Yes Yes Yes No ? 
Pickhardt et 
al. (2008) 
Yes No No Yes Yes Yes No N/A No 
Flicker et al. 
(2008) 
No Yes No Yes
a
 No ?
b
 Yes Yes Yes 
Gluecker et 
al. (2003) 
No No No No No ?
b
 No N/A Yes 
Macari et al. 
(2011) 
No Yes No ? No Yes No N/A ? 
Veerappan 
et al. (2010) 
Yes Yes Yes Yes
a
 No Yes Yes ?
c
 ? 
 
a
 Previously diagnosed ECFs were reported separately 
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b
 Radiologists were board-certified and experienced but CTC-related experience not reported 
c
 Stated that senior radiologist reviewed all scans with significant findings, so likely that it was done with the other radiologist’s report 
 
Aspects of Selection Bias in Included Studies 
 
Author (Year) Confounding Selection Bias 
 
Something distinguishing those 
with ECFs from those without? 
Consecutive enrollment? 
Do dropouts differ from 
those properly followed up? 
More than 30% of cohort lost to 
follow-up? 
Chin et al. (2005) Yes No
a
 N/A
b
 No 
Pickhardt et al. (2008) Yes Yes ? No 
Flicker et al. (2008) ? Yes N/A
b
 No 
Gluecker et al. (2003) ? Yes ? No 
Macari et al. (2011) ? Yes ? No 
Veerappan et al. (2010) No Yes ? No 
 
a
 Randomly selected cohort representing a small percentage of eligible cohort 
b
 No subjects were lost to follow-up 
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Overall Assessment of Internal Validity 
 
Author (Year) Risk of Measurement Bias Risk of Confounding Risk of Selection Bias Overall Internal Validity 
Chin et al. (2005) Low/Medium Medium Low/Medium Fair 
Pickhardt et al. (2008) Medium Medium Low/Medium Fair 
Flicker et al. (2008) Medium Medium Low/Medium Fair 
Gluecker et al. (2003) High Medium Medium Fair 
Macari et al. (2011) High Medium High Fair/Poor 
Veerappan et al. (2010) Medium/High Low Low Fair 
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Appendix H. External Validity Ratings 
External Validity of Population, Setting and Interventions and Overall Generalizability 
 
Author (Year) Population
a
 Setting
b
 Intervention
c
 Overall External Validity 
Chin et al. (2005) Good Fair Fair Fair 
Pickhardt et al. (2008) Good Fair Fair Fair 
Flicker et al. (2008) Poor Fair Fair Fair 
Gluecker et al. (2003) Poor Fair Fair Fair 
Macari et al. (2011) Fair Fair Poor/Fair Fair 
Veerappan et al. (2010) Good Fair Poor/Fair Fair 
 
a 
How closely the study population matches an asymptomatic, average-risk population in the recommended screening age of 50-74 
b
 How well did study settings replicate the mixture of academic and community settings 
c
 How close were study interventions (i.e. CTC modality, radiologist experience, technique of reading CTC) to the typical CTC screening 
programs 
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